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                                                                   ABSTRACT 
 
Introduction 
Diabetes Mellitus is one of the major causes of degenerative diseases worldwide. Long term 
complications of diabetes include hepatic injury characterized by cirrhosis, inflammation, 
apoptosis, and microvascular and macrovascular aberrations. Mechanisms by which diabetes 
induces liver damage include the development of lipotoxicity-induced mitochondrial dysfunction 
and activation of inflammatory pathways that lead to progressive liver damage. Previous studies 
have reported that the leading cause of death in patients with diabetes mellitus is chronic liver 
disease. The liver is a metabolically active organ involved in many vital life functions. It performs 
many activities that are critical for survival. Due to its important activities, the liver is exposed to 
a number of insults and is one of the body's organs most subject to injury. 
Despite considerable progress in modern medicine, there are very few therapeutic agents that can 
protect the liver from hyperglycemia-induced oxidative damage and restore normal liver functions. 
As a result, the search for novel therapies that would be cheaper and effective in the management 
of liver diseases is paramount. Moringa oleifera (MO) is a multipurpose plant traditionally used 
for its medicinal and nutritional properties in many countries, especially in Durban, KwaZulu-
Natal/ South Africa where the material for this study has been harvested. It has been shown to 
possess antihyperglycemic, antioxidant and anti-inflammatory properties and could possibly 
prevent liver injury. This study, therefore, investigated whether MO leaf extracts could mitigate 
hepatotoxicity associated with diabetes mellitus. 
Methods 
Male Wistar rats (250-300 g) were divided into six groups (n=7). Group A was orally treated daily 
with 3.0 ml/kg body weight (BW) of distilled water; group C was similarly treated with MO (500 
mg/kg/BW) daily. Groups B, D, E, and F were rendered diabetic by a single intraperitoneal 
injection of streptozotocin (STZ) (45 mg/kg/BW in 0.1M citrate buffer, pH4.5). Diabetes was 
confirmed 3 days later. Additionally, group D was treated with subcutaneous insulin (2 U/kg/BW, 
bid) while groups E and F were orally treated daily with MO 250 mg/kg/BW and 500 mg/kg/BW, 
respectively. Glucose tolerance tests (GTT) were done on day 47 of the animal treatment. After an 
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overnight fast for 8 hours, rats in all groups were intraperitoneally dosed with a D-glucose solution 
(3.0 g/kg BW) in 0.9% normal saline. This solution was prepared by dissolving 45 g of D-glucose 
anhydrous in 60 ml distilled water (0.75 g/ml). Blood glucose concentrations were measured by 
tail pricking at 0, 30, 60, 90, and 120 minutes, using glucometer (OneTouch select®; Lifescan Inc., 
Milpitas, California, USA). On day 54 of treatment, animals were sacrificed by halothane 
overdose. Blood was collected by cardiac puncture in heparinized tubes then separated into plasma 
and stored at -80˚C for further biochemical analysis. Livers were excised, snap-frozen in liquid 
nitrogen and similarly stored for histological analysis. 
Results: Diabetic animals had significantly (p<0.05) elevated Fasting Blood Glucose (FBG) and 
reduced insulin levels compared to controls. Treatment with either insulin or MO significantly 
(p<0.05) reduced FBG compared to non-treated diabetic rats. Treatment with 500 mg/kgBW 
significantly reduced FBG compared to treatment with 250 mg/kgBW. Calculated Areas-Under-
the Curve (AUCs) from OGTT suggested that untreated diabetic rats exhibited glucose intolerance 
but treatment with either insulin or MO extracts significantly (p<0.05) reversed this. Liver function 
tests defined by Aspartate Aminotransaminase (ASAT), Alanine Aminotransaminase 
(ALAT),gamma-glutamyl aminotransaminase (GGT) and albumin were significantly (p<0.05) 
elevated in untreated diabetic group but treatment with either insulin or MO extracts significantly 
(p<0.05) reversed this. Treatment with 500 mg/kgBW of MO significantly (p<0.05) reduced GGT 
levels compared to treatment with 250 mg/kgBW. Untreated diabetic, unlike MO-treated rats, 
exhibited degeneration of hepatocytes and inflammatory cells infiltration with the fragmentation 
of the nucleus and cell lysis, necrotic hepatocytes, hepatic vein congestion, and vesicular 
cytoplasm compared to normal controls. 
Conclusion: This study has shown that methanolic leaf extracts of MO have dose-dependent 
antidiabetic effects. Liver function tests (ASAT, ALAT, GGT) and albumin were significantly 
elevated in untreated diabetic rats than those treated with MO extracts. This may justify the 
hepatoprotective effects of MO extracts in streptozotocin-induced diabetic rats. 





CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
1.1 DIABETES MELLITUS 
 
1.1.1 Epidemiology of Diabetes Mellitus. 
In 2017, the International Diabetes Federation (IDF) estimated that 425 million adults aged 
between 20 and 79 years were living with diabetes worldwide (Ogurtsova et al., 2017). Globally, 
422 million people were living with diabetes in 2014 and 1.6 million deaths were attributed to 
diabetes (World Health Organization, 2016). IDF estimates that 75% of people with diabetes live 
in low-and-middle-income countries (Whiting et al., 2011). Total global health expenditure due to 
diabetes in 2017 was estimated at 727 billion US dollars (Ogurtsova et al., 2017). 
The National Diabetes Statistics Report estimates that 30.3 million people with diabetes (9.4% of 
the USA population) including 23.1 million people diagnosed and 7.2 million people undiagnosed 
were living with diabetes in the United States in 2017 (Centers for Disease Control and Prevention, 
2017). 
Public health burden of diabetes in Africa has been recognized (Motala et al., 2003). The 
prevalence of diabetes increased from 0-1% in the 1980s to 20% in the 2000s and is predicted to 
be affecting between 18.6 to 23.9 million Africans by the year 2030 (Mbanya et al., 2010). More 
so, 14.2 million Africans were estimated to be living with diabetes in 2015, and this was projected 
to increase to 34.2 million by 2040 (Mutyambizi et al., 2018). It has further been estimated that 
15.5 million adults aged 20-79 years were living with diabetes in Africa in 2017, representing a 
regional prevalence of 3.3% (Ogurtsova et al., 2017). 
In South Africa, 3.5 million people (approximately 6% of the total population) are living with 
diabetes and many others remain undiagnosed (World Health Organization, 2016). The high 
incidence of T2DM in South Africa, like in the rest of the world has been attributed to sedentary 
lifestyle, lack of physical activities and increased urbanization (Menghani et al.,2010). In the year 
2000, the South African National Burden of Disease Study reported that diabetes was the tenth 
leading cause of morbidity and mortality, accounting for about 2.6% of all deaths, which represents  




 1.1.2 Definition and classification of diabetes mellitus 
Diabetes mellitus is a disorder of carbohydrate, lipid and protein metabolism, characterized by 
high blood glucose levels resulting from defects in insulin secretion, insulin action, or both. Long-
term complications of untreated DM include cardiomyopathy, nephropathy, neuropathy and 
retinopathy (Alberti and Zimmet, 1998). Classical symptoms of DM include polydipsia, polyuria, 
blurring of vision and weight loss. As reported by the American Diabetes Association, 4 categories 
of DM are recognized: Type 1 Diabetes mellitus, Type 2 Diabetes mellitus, gestational diabetes 
and diabetes due to secondary disease processes or drugs. Maturity-onset diabetes of the young 
(MODY) is a rare form of diabetes caused by mutations in nuclear transcription factors and 
glucokinase genes which result in pancreatic β-cell dysfunction in the production of insulin 
hormone  (Cydulka and Maloney., 2002; Navale, 2017). 
 
1.1.2.1 Type 1 Diabetes  
 
Type 1 diabetes mellitus (T1DM) is autoimmune-mediated destruction of pancreatic β-cells. The 
dendritic cells and macrophages in the pancreatic islets possess autoantigens and present them to 
autoreactive CD4+ T cells. CD4+ T cells secrete cytokines which can activate cytotoxic T cells 
(CD8+). These cells activate macrophages and other T cells leading to beta cells destruction 
ultimately causing absolute insulin deficiency which predisposes individuals to ketoacidosis 
(Lambert et al., 2004). Genetic and environmental factors have been identified as leading for the 
autoimmune destruction of the β-cells. Human leukocyte antigen (HLA) is a common genetic risk 
factor associated with the development of diabetes (Nokoff and Rewers, 2013). Environmental 
factors involved in the pathogenesis of T1DM include parasites, viruses, and bacteria which 
mediate the direct infection of the pancreatic β-cells or shape the immune system to mutually 
benefit the parasite and the host (David et al., 2004). 
T1DM leads to complete pancreatic ß cell destruction and eventually all patients with T1DM will 
require insulin therapy to maintain glycemic control. Patients with T1DM are rarely obese and are 




All patients with T1DM present with classical symptoms of hyperglycemia and signs of 
ketoacidosis  (David, M. and Nathan., 2009). When the diagnosis is uncertain, other tests can be 
used including the measurement of plasma C-peptide levels or markers of immune destruction 
such as islet cell antibodies, autoantibodies to insulin, autoantibodies to glutamic acid 
decarboxylase (GAD) and autoantibodies to tyrosine phosphatases IA-1 and IA-2 (Casqueiro et 
al., 2012). T1DM usually develops in younger and teenage population (adolescent) although it can 
also occur in adults (Devendra et al., 2004). It has been shown that human leukocyte antigen 
chromosome 6 is a genetic predisposition that is linked to T1DM (Lie et al., 1999). Type 1 diabetes 
accounts for 10% of all diagnosed cases of diabetes in adults worldwide (Adeeyo et al., 2013).  
1.1.2.2 Type 2 Diabetes 
T2DM is insulin independent and develops when there is impaired glucose tolerance, obesity, 
dyslipidemia, insulin resistance (IR), increased hepatic glucose production, pancreatic β-cell 
dysfunction and hyperglycemia (Wu et al., 2014). Insulin usually controls glucose homeostasis by 
stimulation of glucose uptake into peripheral tissues, and by signaling the liver to take up glucose 
and store it as glycogen. Production of advanced glycation end products (AGE), increased 
stimulation of hemodynamic regulation systems such as the renin-angiotensin system (RAS) and 
elevated production of reactive oxygen species (ROS) which are associated with chronic 
hyperglycemia plays a pivotal role in the initiation of diabetic vascular complications (Jakus, 
2004). However, the pancreas lacks antioxidant defense systems antioxidant (due to the absence 
of glutathione peroxidase-1 gene) against ROS (Rahal et al., 2014). In this regard, dyslipidemia is 
initiated by insulin resistance which activates lipoprotein lipase (LPL) in adipocytes. The 
lipoprotein lipases catalyze the release of free fatty acids (FFA) which are taken up by hepatocytes 
leading to the production of triglycerides. Triglycerides then stimulate the production of very low-
Density Lipoproteins (VLDL) which contribute to the increased risk of cardiovascular diseases ( 
Ginsberg, H. and Sung, H, 2012). The specific causes of Type 2 diabetes are not well defined, but 
some factors are incriminated such as environmental, genetic as well as lifestyle changes (Zheng 
et al., 2017). In "prediabetes", blood glucose levels are higher than normal but not yet high enough 
to be diagnosed as diabetes. Research has shown that some long-term damage to the body organs 
especially the heart and circulatory system, may already be occurring during prediabetes (Silva et 
al., 2008). Cardiovascular disease is the foremost killer of patients with diabetes. 
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The metabolic syndrome is a clustering of risk factors that often accompany obesity and associated 
with increased risk for both cardiovascular diseases and type 2 diabetes (Ford et al., 2008). This 
cluster of risk factors led to diabetes and cardiovascular diseases.  Such factors include 
hypertension, insulin resistance, defective glucose metabolism (impaired fasting glycemia or 
glucose intolerance), increased LDL-c, triglycerides, obesity and low HDL-c concentrations (Paula 
et al., 2013a). European Group for Study of Insulin Resistance (EGIR), International Diabetes 
Federation (IDF), American Association of Clinical Endocrinologists (AACE), WHO clinical 
criteria (WHO 1999) and the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP/ATP III) have defined the criteria classification of metabolic syndrome (Table 1) (Paula et 
al., 2013b). These groups have a harmonized definition of the metabolic syndrome with criteria 
defined in Table 1 below. 
Table 1: The definition of metabolic syndrome by different criteria (Alberti and Zimmet., 1998; 
Einhorn et al., 2003). Legend: BMI: body mass index; DM: diabetes mellitus; FBG: fasting 
blood glucose; IFG; impaired fasting glucose; IGT: impaired glucose tolerance; IR: insulin 
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females 
TGs ≥ 150 mg/dl 
and 
HDL-c < 40 
mg/dl in 
males or < 50 
mg/dl in 
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IGT or IFG 
(None 
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The major causes of metabolic syndrome include genetic and environmental factors which 
influence both lipid and glucose metabolism. An estimated 20-25% of the adult individuals have 
been clinically diagnosed with metabolic syndrome globally (Moreira et al., 2014). 
 Genes that  control the expression of lipases, adiponectin, uncoupling proteins , β-Adrenergic 
receptors, PPAR-γ, glycoprotein PC-1, skeletal muscle glycogen synthase 1, IRS-1, Calpain-10, 
CD36, fatty acid binding protein-2, apolipoprotein E, upstream transcription factor 1 and 11 β-
hydroxysteroid dehydrogenase type 1 have associated with increased incidence of metabolic 
syndrome (Stancakova and Laakso., 2014). Pro-inflammatory cytokines like tumor necrosis factor 
(TNF) and Interleukin 1-β (IL1-β), C-reactive protein and neuropeptide Y(NPY),  leptin receptor, 
pro-opiomelanocortin (POMC) and melanocortin receptors are also involved in metabolic 
syndrome (Groop, 2007).  
Environmental factors that lead to metabolic syndrome include physical inactivity, obesity, 
smoking and aging, which have been suggested to induce insulin resistance, cardiovascular 
disorders, inflammation, hyperinsulinemia and endothelial dysfunction (Takashi et al., 2006). 
These factors are associated with dysfunctions of adipocytes leading to altered production of 
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hormones and cytokines such as interleukin-6 (IL-6), TNF-α, resistin, adiponectin, and leptin 
(Takashi et al., 2006). 
 
1.1.2.3 Gestational Diabetes 
 
Gestational diabetes is defined as glucose intolerance with first recognition pregnancy. Women 
who are overweight, had gestational diabetes before or have a family history of diabetes are at a 
higher risk of developing gestational diabetes. Untreated gestational diabetes may cause problems 
to the fetus such as breathing difficulties and low blood sugar levels. Gestational diabetes is 
associated with increased risk of maternal and fetal complications. Fetal macrosomia is a common 
complication of diabetes in pregnancy. Pregnant woman of a macrosomic fetus is at increased risk 
for preeclampsia, labor abnormalities, severe perineal lacerations, risks of preterm birth and 
cesarean section. The fetus is at risk for stillbirth, intracranial hemorrhage, shoulder dystocia and 
malformations (Susa JB, 1988). The neonate is at risk for hyperbilirubinemia, hypocalcemia, 
hypoglycemia, hypomagnesemia, polycythemia and neonatal cardiomyopathy (Macintosh MC et 
al., 2006). Fetal macrosomia is caused by fetal hyperinsulinemia that occurs as a physiological 
response to maternal hyperglycemia (Moreli et al., 2016). 
Later in life, the baby may be at an increased risk for obesity and T2DM for the rest of their lives 
(Reece, 2010). 
 
1.1.3 Pathophysiology and major risk factors for T2DM 
 
Type 2 diabetes is caused by a combination of genetic factors related to impaired insulin secretion 
and insulin resistance and environmental factors such as lack of exercise, aging, stress as well as 
obesity. Impaired insulin secretion and insulin resistance contribute jointly to the development of 
pathophysiological conditions. Although the pathogenesis of T2DM has been attributed mainly on 
insulin and beta-cell dysfunction, an abnormal increase in alpha-cell function which results in 
hyperglucagonemia and consequent hepatic glucose production has long been recognized as a 
contributory factor to hyperglycemia in diabetic patients. Postprandial state in T2DM patients is 
characterized by elevated fasting concentrations of glucagon, impaired glucose-induced glucagon 
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suppression, and disrupted insulin–glucagon interaction against those of healthy subjects. 
Alterations in the cross-talk between beta- and alpha-cells may underlie diminished mass of insulin 
pulses and hyperglucagonemia in T2DM patients (Menge et al., 2011). Because of resistance to 
the actions of insulin and reduced insulin secretion, tissues such as skeletal muscles, liver, and 
adipose tissues are affected, leading to elevated blood glucose levels (Stumvoll et al., 2005). In 
T2DM, insulin resistance plays an important role due to increased gluconeogenesis and decreased 
glucose uptake in the skeletal muscles and adipose tissues at a regular plasma insulin level. In 
addition, β-cell dysfunction results in reduced insulin release, which is not enough for maintaining 
normal glucose levels (Weyer et al., 1999).  
 
 
Figure 1: Consequences of insulin action/inaction in Type 2 diabetes mellitus. 
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Insulin secretion from the β-cells in the pancreas normally suppresses gluconeogenesis and 
increases glucose uptake by skeletal muscles and adipose tissues. Diminished pancreatic β-cells 
function leads to hyperglycemia (Zheng et al., 2017). 
  
Major risk factors for T2DM  
There are many factors that contribute to T2DM such as: 
 Older age   
 The family history of type 2 diabetes mellitus (T2DM) 
  Low socioeconomic status 
 Genetic factors (for example, carrying risk alleles in the TCF7L2 gene) 
  Components of the metabolic syndrome (increased waist circumference, 
increased blood pressure, increased plasma levels of triglycerides, low plasma 
levels of HDL cholesterol and small, dense LDL cholesterol particles) 
  Overweight or obese (BMI ≥25 kg/m
2
) 
 Abdominal or central obesity (independent of BMI) 
  Cigarette smoking 
  Sedentary lifestyle 
  History of gestational diabetes mellitus or delivery of neonates >4 kg in weight. 
  Some medications, such as statins, thiazides, and beta-blockers 
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1.1.4 Complications of diabetes. 
 
Persistent hyperglycemia leads to both acute and chronic complications. Major tissues affected by 
hyperglycemia are nervous system, the retina of eye, kidney, adipose tissue, liver and pancreatic 
β cells. T1DM and T2DM both result in long term macro and microvascular complications. 
Microvascular complications include diabetic retinopathy, neuropathy, and nephropathy, while 
macrovascular complications include coronary artery diseases, peripheral vascular disease, and 
stroke (Casqueiro, et al., 2012). Diabetic Ketoacidosis (DKA) is one of the major acute 
complications of T1DM characterized by ketoacidosis and electrolyte imbalances, caused by 
absolute lack of insulin; characterized by dehydration and lipolysis (Cydulka et al.,2002). In DKA, 
there is a deficiency of insulin, which results in increased plasma catabolic hormones, that cause 
overproduction of glucose (Aronson and Ferner, 2003). In renal tubes, excess glucose draws water 
and electrolytes such as calcium, magnesium, potassium, and sodium into the urine, from the 
circulation. This osmotic diuresis causes dehydration and other electrolyte imbalances associated 
with diabetic ketoacidosis (Cydulka et al.,2002).  
 
1.1.4.1 Diabetic Retinopathy. 
 
Diabetic retinopathy is one of the most common complications of untreated DM and leads to visual 
impairment and blindness in adults aged between 20-74 years ( Lilly et al., 2006; Forbes and  
Cooper, 2013). Lesions in the retina cause alterations of retinal structures such as changes in 
vascular permeability, capillary degeneration, capillary microaneurysms, and neovascularization 
by increased formation of new blood vessels (Lilly et al., 2006). Functional impairment of the 
neural retina alters retinal electrophysiology which results in an inability to differentiate between 
colors (Forbes & Cooper, 2013).  The development and progression of DM are dependent on the 
severity and duration of hyperglycemia. 
Clinically, diabetic retinopathy is divided into non- proliferative and proliferative disease phases. 
In the initial phase, hyperglycemia can lead to intramural pericyte (cells that wrap around the 
endothelial cells of capillaries and venules throughout the body)  death and thickening of the 
basement membrane, which contribute to changes in the integrity of blood vessels within the 
13 
 
retina, altering the blood-retinal barrier and vascular permeability (Watkins, 2003). During this 
primary phase of nonproliferative diabetic retinopathy (NPDR), no visual impairment is noticed. 
Degeneration or occlusion of retinal capillaries is associated with failing prognosis, which is most 
likely the result of ischemia followed by subsequent release of angiogenic factors including those 
related to hypoxia (Osborne N.et al., 2004). 
In the proliferative phase neovascularization and accumulation of fluid within the retina, called 
macular edema, contribute to visual damage. In more severe cases, there can be bleeding with 
associated distortion of the retinal architecture including the development of a fibrovascular 
membrane which can subsequently lead to retinal detachment (Sikorski et al., 2013). 
Diabetic retinopathy can be prevented with early diagnosis and treatment. 
In order to maintain glycemic control and blood pressure, treatments with an injection of the steroid 
triamcinolone, laser photocoagulation, and vascular endothelial growth factor (VEGF) antagonists 
into the eye, and vitrectomy, to remove the vitreous (Forbes & Cooper, 2013). However, newer 
agents have been developed (Table 2). 
 
Table 2: Potential therapies in the treatment of diabetic retinopathy (Nawaz et al., 2013). 
Targets    Drug 
Inhibitor of AGE formation Pyridoxamine, Aminoguanidine, OPB-9195, ALT-
946, ALT-711, LR-90, N-PheracylThiazolium 
Bromide (PTB), Alagebrium. 
 
Protein kinase C (PKCs) inhibitors. 
 
Ruboxistaurin (RBX), PKC412. 
 
Aldose reductase Inhibitors (ARIs). 
 
Sorbinil, Tolrestat, Epalrestat, Lidorestat, Zenarestat, 
Ranirestat, Ponalrestat, Zopolrestat, ARI-809, 
Fidarestat. 
Nonsteroidal anti-inflammatory drugs 
(NSAIDs) 
Aspirin, Nepafenac, Sodium salicylate, Sulfasalazine, 






1.1.4.2 Diabetic Neuropathy 
 
Diabetic neuropathy is characterized by a progressive loss of nerve fibers affecting both the 
autonomic and somatic divisions. It is defined by impaired damage healing due to a decrease in 
oxygen in tissues because of glycated hemoglobin and altered immune system (Schalkwijk, 2008). 
As with other microvascular complications, the risk of developing diabetic neuropathy is relative 
to chronic glucose intolerance even though some individuals may have a genetic predisposition  
(Dobretsov et al., 2007). 
There are two classes of diabetic neuropathies: diabetic polyneuropathy in which hyperglycemia 
causes diffuse damage to the peripheral nervous system; and mononeuropathy, where nerve 
damage is focal (Boulton, A.J., 2005). Polyneuropathy is the most common form of diabetic 
neuropathy and may present as cranial, autonomic neuropathy and peripheral motor neuropathy. 
While mononeuropathies include Carpal Tunnel Syndrome (CTS) and Ulnar Neuropathy at the 
Elbow (UNE). Both polyneuropathy and mononeuropathy play significant roles in sensory and 
motor deficits and are both associated with debility in patients (Zochodne, 2007). 
The precise nature of the injury to the peripheral nerves from hyperglycemia is not known but it 
may be related to mechanisms such as polyol accumulation, injury from AGEs, and oxidative 
stress. AGEs play significant roles in sensory and motor deficits; they induce expression of 
inflammatory genes resulting in neurologic dysfunction and altered pain sensation (Herold et al., 
2007). 
Up to 80% of amputations occur after foot ulceration or injury, which can result from diabetic 
neuropathy (Doupis, J. and Alexiadou, K., 2012). 
 Neurological dysfunction can affect gastrointestinal system, cardiovascular system or 
reproductive system; and can be manifested by neuropathy signs such as bladder dysfunction, 
constipation, diarrhea, erectile dysfunction, exercise intolerance, resting tachycardia, silent 
ischemia, and sudden cardiac arrest (Kempler et al., 2011). 
Current management of diabetic neuropathy is mainly based on symptoms. Analgesics are used to 
tranquilize pain. However, in severe conditions, opiates such as amitriptyline, gabapentin, 
duloxetine, and pregabalin may be required (Boulton et al., 2005). Management of peripheral 
neuropathy requires holistic approach and patients should be informed about the importance of 
foot care and regular checkups (Navale, 2017). Autonomic neuropathy manifests as gastroparesis 
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and erectile dysfunction and has devastating effects on lifestyle. Cases of gastroparesis are usually 
treated with domperidone, erythromycin, and metoclopramide, as well as dietary changes. 
However, severe cases may require implantation of electrodes to stimulate gastric contractions 
(Boulton, A.J. et al., 2005). 
 
1.1.4.3 Diabetic Nephropathy (DN). 
Diabetic nephropathy is defined as “microalbuminuria or macroalbuminuria and impaired renal 
function characterized by elevated serum creatinine, reduced creatinine clearance, or increased 
glomerular filtration rate”(Navale, 2017). 
Predisposing factors to DN include hemodynamic changes, metabolic changes, as well as 
environmental and genetic factors. Elevated serum AGEs levels that occur as a result of 
hyperglycemia have been found in nephropathic kidneys (Lilly et al., 2006). Hemodynamic 
changes occur early in diabetic nephropathy and are often characterized by glomerular 
hyperfiltration (Forbes et al.,2013). DN is the leading cause of chronic kidney disease and serves 
as a risk factor for diabetic cardiomyopathy (Ronco et al., 2010). DN is defined by the presence of 
proteinuria >0.5 g/24 h and is categorized into stages based on urinary albumin excretion (ADA, 
2005). The cutoff values (timed, 24-h, and spot urine collection) for the diagnosis of 
microalbuminuria and macroalbuminuria is 30-299 mg/24h and ≥300 mg/24h respectively (ADA, 
2004). DN is clinically characterized by the thickening of the glomerular basement membrane, and 
accumulation of matrix material in the mesangium. This is followed by nodular deposits, and 
glomerulosclerosis. At the terminal stage, the glomeruli are lost, hence the function of the kidney 
declines (Marshall, 2016). 
Treatment is focused on control in blood glucose, dyslipidemia, hypertension, microalbuminuria, 
smoking cessation, and weight management. However, anemia, acidosis and bone disease, as well 
as malnutrition are common conditions secondary to renal disease, which also need to be treated 
(Levey and Coresh, 2012). Reduction in blood pressure is vital in the prevention and treatment of 
DN. The target blood pressure of 120-130 mm Hg is recommended for patients of T2DM to 
prevent loss of renal function and prevention of diabetic nephropathy ( Grassi, G. et al., 2016). In 




Treatment of DN includes blockade of Renin-Angiotensin-Aldosterone System (RAAS) with ACE 
inhibitors or angiotensin receptor blocker drugs with maximum tolerable doses. Treatment with 
ACE inhibitors in clinical studies has demonstrated a reduction in the progression of nephropathy 
in diabetic patients (Lewis et al., 1993).  
 
1.1.4.4 Diabetic cardiomyopathy (DCM). 
 
Diabetic cardiomyopathy is defined as functional and structural changes in myocardium associated 
with diabetes without coronary artery disease. It is one of the causes of heart failure in diabetic 
patients besides myocardial ischemia and coronary artery disease.  Diabetes mellitus affects the 
heart by mechanisms including cardiac autonomic dysfunction, inflammation, maladaptive 
immune response, metabolic disturbance, microvascular impairment, and subcellular 
abnormalities (Lee and Kim, 2017). Activation of the Renin-Angiotensin-Aldosterone System 
(RAAS) and oxidative stress are also proposed mechanisms of DCM ( Pappachan et al., 2013; Jia 
et al., 2016). Hyperglycemia, hyperlipidemia, and inflammation stimulate the production of 
Reactive Nitrogen Species (RNS) or ROS that cause diabetic complications, including DCM 
(Inoguchi et al., 2000). Adaptive responses to these metabolic abnormalities result in cardiac 
dysfunction and heart failure (Pappachan et al., 2013). 
DCM can be asymptomatic in first phases, however, in later phases it may appear as overt heart 
failure. Patients develop symptoms related to advanced heart failure or previous heart failure or 
both due to lack of pumping ability or impaired venous dumping due to congestion. Angina 
pectoris, dyspnea, edema in lower extremities, fatigue, hepatomegaly, increased jugular vein 
pressure, syncope and weakness may appear as symptoms of failing cardiac function (Miki et al., 
2013). 
Echocardiography can show diastolic dysfunction even in asymptomatic patients and those without 
any cardiac hypertrophic modifications. Vital aspects of treatment are the minimization of cardiac 
risk factors, lifestyle changes, regulation of blood glucose levels, and therapy of heart failure in a 
patient with overt cardiac damage (Ogihara et al., 2009). 
Many clinical trials showed that an improvement of glycemic control has been shown to be 
associated with improved parameters of outcome in diabetic cardiomyopathy. Management of 
T2DM is associated with improved management options for patients with DCM. Metformin has 
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been shown to up-regulate cardiomyocyte autophagy that has a role in the prevention of DCM in 
animal models. Glucagon-like Peptide-1 (GLP-1) is a peptide hormone, secreted by the L-cells of 
jejunum and ileum of the small intestine that stimulates meal-related endogenous insulin secretion. 
The use of this drug in obese T2DM patients is associated with improvement in glycemic control 
and weight loss. This drugs may emerge as a promising treatment option in obese T2DM patients 
with DCM (Xie et al., 2011).  
 
1.1.5 Diagnosis of Diabetes Mellitus 
 
Diabetes can be diagnosed based on blood glucose criteria, either the Fasting Blood Glucose or 
the 2-hours Blood glucose (2-h BG) value after a 75 g oral glucose tolerance test (OGTT) or 
HbA1C criteria (Eric, S., 2009). These tests are used for diagnosis of DM in addition to clinical 
features and family history of the patient. However, it is essential to consider age, anemia or 
hemoglobinopathies and race in patients while interpreting the results. Table 3 describes the 
criteria for classification and diagnosis of the diabetic state of the patient (American Diabetes 
Association, 2017). 
 
Table 3: Criteria for diagnosis of DM (American Diabetes Association, 2017). 
 
 Normal Prediabetes Diabetes 
Random plasma glucose levels < 11.1 mmol/l 
 
      N/A 
 
≥ 11.1 mmol/l 
 




≥ 7.0 mmol/l 
 
2-hours blood glucose value 
after a 75g oral glucose 
tolerance test 




≥ 11.1 mmol/l 
 








1.1.6 Management and current treatment for diabetes mellitus. 
 
Insulin is the main drug for the management of T1DM. Biotechnologically produced insulin is less 
likely to cause allergic reactions in diabetics. This form of insulin is absorbed more rapidly than 
animal-derived insulin thus showing its effectiveness in a shorter duration. Table 4 describes 




























Table 4: Drugs approved by the FDA for the treatment of Type 2 DM (Navale, 2017). 
 






Reduce postprandial blood  





Biguanides Metformin Decrease in hepatic 
gluconeogenesis and increased 
skeletal muscle glucose uptake 






Bromocriptine Reduces insulin resistance 











dipeptidyl peptidase reducing 
degradation of incretin 









Stimulate insulin secretion, 
slows gastric emptying, 
suppresses glucagon levels and 










Stimulate insulin secretion 
from β cells. 
Risk of  
hypoglycemia 
Sulfonylureas: 
first generation    






Secretion from β cells 
Hypoglycemia 
Thiazolidinediones Pioglitazone Agonist at PPAR-γ 
receptors, improves insulin 
sensitivity in peripheral 
tissues. 
Edema 
Amylin analogs Pramlintide 
acetate 






potassium channels, stimulates 
insulin release from pancreatic 
β cells. 
Hypoglycemia, 




SGLT2 inhibitors Dapagliflozin, 
Canagliflozin, 
Empagliflozin 
Decrease renal glucose 
reabsorption and thereby 
enhancing urinary glucose 
excretion and subsequent 
reductions in plasma glucose 
and glycosylated hemoglobin 
concentration. 
Urinary and genital 











Binds to the insulin receptor 
activates glucose transport 
GLUT4. PIP3 and tyrosine 
phosphorylated guanine 
nucleotide exchange proteins, 
facilitates GLUT4 translocation 


























 1.2 LIVER DISEASE AND DIABETES. 
 
1.2.1 Structure of liver 
 
The liver is the largest organ in the human body which is located below the diaphragm in the right 
upper quadrant of the abdominal cavity. The liver is roughly triangular and consists of two lobes: 
a larger right lobe and a smaller left lobe. The lobes are separated by the falciform ligament, a 
band of tissue that keeps it anchored to the diaphragm. An adult's liver weighs around 1.5 kg and 
extends approximately from the right 5th rib to the lower border of the rib cage. The internal 
structure of the liver is made of around 100,000 small hexagonal functional units known as lobules 
(Ramadori et al., 2008). Each lobule consists of a central vein surrounded by 6 hepatic portal veins 
and 6 hepatic arteries. These blood vessels are connected by many capillary-like tubes called 
sinusoids. Each sinusoid passes through liver tissue containing 2 main cell types including Kupffer 
cells and hepatocytes. Kupffer cells are a type of macrophage that capture and break down old, 
worn out red blood cells passing through the sinusoids whereas; hepatocytes are the working cells 
of the liver that have a unique capacity to reproduce in response to liver injury. The hepatocytes 
of the liver are tasked with many of the essential metabolic functions that support the cells of the 
body (Ramadori et al., 2008). 
 
1.2.2 Functions of liver 
 
The liver plays a major role in the regulation of many of physiological processes in our bodies, 
which include metabolic, vascular, immunological, storing, secretory and excretory functions. 
Furthermore, it is involved in detoxification of a variety of drugs and xenobiotics. Also, it plays a 
key role in the carbohydrate, protein and fat metabolism in the human body (El-bakry et al., 2016). 
The digestive system breaks down carbohydrates into monosaccharides, which cells use as a 
primary energy source. Blood which enters the liver through hepatic portal vein is rich in glucose 
from digested food. Hepatocytes receive this glucose and store it as the macromolecule glycogen, 
a branched polysaccharide that allows the hepatocytes to collect large amounts of glucose and 
quickly release glucose between meals. The absorption and release of glucose by the hepatocytes 
22 
 
help to maintain homeostasis and protects the rest of the body from elevation and drops in the 
blood glucose level (Jensen et al., 2011). 
When amino acids enter the liver, they require metabolic processing before they can be used as an 
energy source. Hepatocytes remove the amine groups of the amino acids and transform them into 
ammoniac and eventually urea. Urea is less toxic than ammonia and can be excreted in urine as a 
waste product of metabolism. The remaining parts of the amino acids can be broken down into 
ATP or transformed into new glucose molecules (Wu, 2009). 
The liver synthesizes and excretes bile necessary for digestion and absorption of fats. It also helps 
in the absorption of vitamin K from the diet. The emulsification of fats by bile turns the large 
clumps of fat into smaller pieces that have more surface area and are therefore easier for the body 
to digest (Panjaliya et al., 2013). 
Liver stores vitamins such as vitamins A, D, E, K, and B12, and the minerals iron and copper in 
order to provide a continuous supply of these important substances to body tissues. 
The liver plays a crucial role in detoxifying substances that are harmful to the body; as blood from 
the digestive organs passes through the hepatic portal circulation, the hepatocytes of the liver 
monitor the contents of the blood and remove many potentially toxic substances before they can 
reach the rest of the body (Panjaliya et al., 2013). 
The liver function is an organ immune system through the function of the Kupffer cells that line 
its sinusoids. Kupffer cells are a type of fixed macrophage that forms part of the mononuclear 
phagocyte system along with macrophages in the spleen and lymph nodes. Kupffer cells play an 
important role by trapping parasites, bacteria, fungi, cellular debris and worn-out blood cells 
(Ramadori et al., 2008). 
The liver produces several vital protein components of blood plasma including albumins, 
fibrinogen, and prothrombin. Albumins are proteins that maintain colloidal osmotic pressure 
(Yang and Monti., 2017). 
 
1.2.3 Clinical signs of liver diseases 
 
Jaundice: Jaundice refers to the staining of tissue with bilirubin or bilirubin complexes. It is 
detectable when the plasma bilirubin exceeds 50 mmol/L (3 mg/dl). The staining is much more 
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pronounced with conjugated bilirubin (direct), than with unconjugated bilirubin (Ullah et al., 
2016). 
The usual divisions of jaundice are: 
• Hemolytic jaundice (pre hepatic) – increased bilirubin load for the liver cells. 
• Hepatocellular jaundice (hepatic or toxic) – defects in conjugation. 
• Cholestatic jaundice (obstructive or post-hepatic), including hepatocellular (parenchymal) liver 
disease and large duct obstruction (Ullah et al., 2016) 
Hepatic encephalopathy: 
Hepatic encephalopathy (HE) is a term used to describe a spectrum of neuropsychiatric 
abnormalities in patients with significant liver disease. HE is classified as type A, B, or C based 
on the underlying mechanism causing the encephalopathy. Type A is caused by acute liver failure, 
whereas type B is primarily caused by portosystemic shunting of blood in the absence of liver 
disease and type C is resulting from cirrhosis of the liver with portal hypertension (Bajaj et al., 
2009). Lactulose is used to treat or to prevent HE. 
In a patient with known or suspected of liver disease, the following clinical features are key to 
diagnosing overt HE: impaired orientation; agitation; reduced awareness of surroundings 
succeeded by drowsiness, stupor, and coma; changes in consciousness, rigidities, tremors, and 
alteration in reflexes (Salgado, M., 2013). Asterixis (flapping tremor) is observed as rhythmic 
bursts (3-4 per second) of flexion-extension movements of the metacarpophalangeal joints, along 
with the side-to-side movement of fingers with the active maintenance of posture. These 
movements are also associated with flexion-extension and radial-ulnar deviation of the wrists 
(Salgado, M., 2013). 
Edema and emaciation: In liver failure, there is a low metabolism protein and amino acid which 
is manifested by tissue wasting and a fall of plasma protein causing edema as a result of lowering 
the osmotic pressure of the plasma. 
Diarrhea and constipation: Bile salts have laxative and disinfectant effects, so if they are low or 
absent in the alimentary tract due to hepatitis, hepatic fibrosis or obstruction of the biliary system, 
constipation punctuated by attacks of diarrhea may ensue. The feces are pale in color with high-
fat contents (steatorrhea). 
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Hemorrhagic diathesis: This occurs in severe diseases of the liver due to a deficiency in 
prothrombin formation and retardation of the fat-soluble vitamin production (Vit K) (Per H et al., 
2013). 
 
Abdominal pain: Abdominal pain in liver diseases is caused by enlargement of the liver with 
increased tension and lesions of the capsule. 
 
1.2.4 Mechanisms of diabetes-associated liver damage 
 
To appreciate the many physical and biochemical alterations that occur in the liver in the presence 
of diabetes, and to recognize how the liver disease may affect glucose metabolism, understanding 
of the role of the liver in the regulation of carbohydrate homeostasis is essential. The liver uses 
glucose and also has the ability to store it as glycogen and synthesize it from non-carbohydrate 
precursors (gluconeogenesis) (Mohamed, J. et al., 2016). Approximately 70% of persons with 
T2DM have fatty liver, with necro-inflammation and fibrosis. Evidence suggests that it is not 
steatosis but the development of lipotoxicity induced-mitochondrial dysfunction and activation of 
inflammatory pathways that lead to progressive liver damage (Cusi, 2009). 
Insulin resistance appears to be a critical contributing factor in the pathogenesis of nonalcoholic 
fatty liver disease (NAFLD), with obesity as the most common cause of the insulin resistant state. 
As body fat stores expand with calorie excess and progressive obesity, alterations in lipid 
metabolism together with inflammation in adipose tissue and ectopic sites of fat deposition lead to 
insulin resistance predominantly secondary to post-receptor abnormalities in insulin signaling 
pathways (Andreas and Gerald., 2014). Synthesis of excess triglyceride in the liver is driven by 
the supply of fatty acids and the accumulation of excess liver fat which is further exacerbated by 
impaired hepatic fatty acid oxidation secondary to insulin resistance (Bhatt and Smith, 2015). 
Insulin resistance most commonly is associated with NAFLD in the context of obesity, and the 
development and progression of NAFLD usually occur in association with both insulin resistance 
and a state of ongoing excess calorie intake. There may not only be an increased risk for NAFLD 
secondary to diabetes, but there also is evidence suggesting that NAFLD conversely may be a risk 




1.2.5 Assessment of liver damage 
Liver function tests are commonly used in clinical practice to screen for liver complications and 
disease, monitor the progression of the known disease, and the effects of potentially hepatotoxic 
drugs. The most common liver function tests include measurement of plasma/serum Alanine 
Aminotransaminase (ALAT), Aspartate Aminotransaminase (ASAT), Gama-Glutamyltransferase 
(GGT) and albumin (Harris, 2005). 
ALAT and ASAT catalyze the reductive transfer of an amino group from alanine or aspartate, to 
alpha-ketoglutarate to become glutamate and pyruvate or oxaloacetate, respectively. Damaged 
hepatocytes release their contents including ALAT and ASAT into the extracellular space. The 
released enzymes ultimately enter into circulation. ASAT has a broader tissue distribution than 
ALAT and perturbations in ASAT levels can occur in response to diseases or injuries in multiple 
tissues including skeletal muscles, brain, liver, and heart. ALAT is primarily found in the liver 
with lower enzymatic activities in the heart tissue and skeletal muscles (Ozer et al., 2008). GGT 
is present on the surface of most cell types and highly active in liver, kidney, and pancreas. It has 
been considered the most specific marker for liver injury. GGT is responsible for the catabolism 
of extracellular glutathione and may be linked to oxidative stress and chronic inflammation, which 
are also important pathways for Type 2 diabetes development  (Wang et al 2016). 
Albumins is the most abundant protein in plasma and is synthesized in the liver. Serum albumin is 
a reliable prognostic indicator for liver disease, nephritic syndrome, malnutrition, and protein-
losing enteropathies (Levitt DG and Levitt MD., 2016). The main function of albumins is to 
maintain colloidal osmotic pressure in plasma. In addition, albumin assists in the transport of 









1.3 MEDICINAL PLANTS AS SOURCES OF PUTATIVE THERAPEUTIC AGENTS. 
Plants as medicines are mentioned in historic documents dating back many thousands of years. 
The plants have been used for years to treat diseases (Petrovska, 2012). 
It is estimated that 80% of the world population is dependent on traditional medicines for primary 
healthcare (WHO, 2013). This dependence is significantly due to the fact that plants are considered 
the only available, affordable and trusted medicine to bring about sustainable solutions to health 
problems. In spite of considerable progress in modern medicine, there are very few therapeutic 
agents that can protect the liver from damage and stimulate liver functions (Pathan M et al., 2014). 
Patients with chronic liver disease are liable to have liver transplantation, which is not only costly 
but has long-term consequences of immunosuppressive agents, especially hyperlipidemia, 
hypertension and renal disease (Detlef S and Nezam, 2009). For these reasons, many patients with 
liver disease use herbal remedies to solve their health problems (Simon P et al., 2010). 
In South Africa, there is growing interest in natural plant-based remedies as a source for treatment. 
Up to 80% of the South African population use traditional medicines to meet their primary health 
care needs (Street and Prinsloo, 2013). 
 
1.3.1 Medicinal plants used in diabetes management in South Africa. 
 
A study conducted by Oyedemi et al., (2009) in South Africa especially in the Eastern Cape 
province, showed that 15 different plant species belonging to thirteen families are used by the 
traditional healers where Strychnos henningsii and Leonotis leonorus were the most cited plants in 
the study. Another study from Limpopo Province South Africa reported that 52 traditional healers 
interviewed recommended 24 plant species belonging to 20 families for the treatment of diabetes 
mellitus (Semenya et al., 2012). The most commonly used plants were Aloe marlothii, 






1.3.2 The plant: Moringa oleifera 








1.3.2.1 Classification  
Plant Name:  Moringa oleifera 
Family: Moringaceae 
Genus: Moringa 
Species: Oleifera L 
 
1.3.2.2 Botanical description: synonyms (Mishra et al., 2011). 
 
 Latin          : Moringa oleifera  
Sanskrit      : Subhanjana  
Hindi          : Saguna, Sainjna  
Gujarati      : Suragavo  
Tamil          : Morigkai  
Telugu        : Mulaga, Munaga  
Malayalam : Murinna, Sigru  
Punjabi       : Sainjna, Soanjna  
Unani         : Sahajan  
Ayurvedic  : Akshiva, Haritashaaka, Raktaka, Tikshnagandhaa  
Arabian      : Rawag  
French        : Moringe à graine ailée, Morungue  
Spanish       : Ángela, Ben, Moringa  
Portuguese  : Moringa, Moringueiro  
Chinese       : La ken  
English        : Drumstick tree, Horseradish tree, Ben tree 
 
1.3.2.3 Geographical source and morphology. 
Moringa oleifera is the most widely used and Moringaceae family with 13 species. It is a fast-
growing, drought-resistant tree that is native to the sub-Himalayan tracts of Afghanistan, 
Bangladesh, India, and Pakistan; but now dispersed worldwide in the tropics and subtropics. 
Moringa grows best in dry sandy soil, it tolerates poor soil, including coastal areas (Ray et al., 
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2006). The plant is a domestic tree in South Africa and is commonly planted in Durban and 
surrounding areas. Moringa oleifera is a small, fast-growing evergreen or deciduous tree that 
usually grows as high as 9 m, with soft and white wood and corky and gummy bark. Roots have 
the taste of horseradish. Leaves are longitudinally cracked, 30-75 cm long main axis and its branch 
jointed, glandular at joints, leaflets are glabrous and entire. The leaflets are finely hairy, green and 
almost hairless on the upper surface, paler and hairless beneath, with red-tinged mid-veins, with 
entire (not toothed) margins, and are rounded or blunt-pointed at the apex and short-pointed at the 
base. The twigs are finely hairy and green. Flowers are white, scented in large axillary down 
panicles, pods are pendulous, ribbed, seeds are 3-angled (Mishra et al., 2011). 
 
1.3.2.4 Bioactive compounds of Moringa oleifera. 
Moringa oleifera has an impressive range of medicinal uses with high nutritional value and 
medicinal benefits. Different parts of Moringa tree contain protein, vitamins A, B1, B2, B3, C, and 
minerals such as calcium, iron, magnesium, and phosphorus ( Gowrishankar et al., 2010). Bioactive 
nutritional and medicinal compounds are found in its roots, bark, leaves, flowers, fruits and seeds. 
Phytochemical analysis has shown that the leaves, flowers and pods are good sources of protein, 
vitamins A, B and C, riboflavin, ascorbic acid,  nicotinic acid, folic acid, pyridoxine, beta-carotene, 
amino acids, iron, calcium, alpha-tocopherol, flavonoids (quercetin, kaempferol) and various 
phenols (Mbikay, 2012; Chinedu et al., 2015). 
The root and bark contain two alkaloids: moringine and moringinine. Other isolated compounds 
from plants are 4 - (4'-Oacetyl – α - L- rhamnopyranosyloxy) benzyl, 4 - (-L rhamnopyranosyloxy) 
benzyl isothiocyanate, niazimicin, pterygospermin, benzyl isothiocyanate, and 4 - (α-L-
rhamnopyranosyloxy) benzylglucosinolate4 (Mishra et al., 2011). 
Pharmacological studies of Moringa oleifera. 
Pharmacological studies have suggested that MO have antioxidant, antiatherosclerotic, 
hypolipidaemic, antitumoral, antipyretic, anti-inflammatory, antiulcer, antispasmodic, diuretic, 
antibacterial and antifungal properties (See table 4 for references). MO leaf is known to be non-
toxic to animals at high doses. A study performed by Ekundina et al., (2015) testing the 
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hepatotoxicity and nephrotoxicity of ethanolic extract of Moringa oleifera on liver and kidney at 
doses of 400, 600 and 800 mg/kg did not show any visible lesions or disease. 
Table 5: Pharmacological actions of Moringa oleifera. 






(Anwar et al., 2007) Aqueous leaf extracts 
Anti-atherosclerotic. 
 
(Chumark et al., 2008) Aqueous leaf extracts 
Anti‐bacteria  
 
(Rahman & Sheikh, 2009)  Aqueous leaf extracts 
Anti-cancer  
 
(Vasanth et al., 2014) Stem bark 
Anti‐diabetic  
 
(Gupta et al., 2012; Aja et al., 
2015) 
Aqueous leaf extracts 
Anti-fungal.  
 
(Kekuda et al., 2010; Al-




(Anwar et al., 2007) Aqueous leaf extracts 
Antihyperglycemic 
 
( Jaiswal et al., 2009; Edoga et 
al., 2013) 
Aqueous leaf extracts 
Anti-pyretic. 
 
(Aney et al., 2009) Aqueous leaf extracts 
Anti-inflammatory.  
 
(Anwar et al., 2007)  Aqueous leaf extracts 
Anti-oxidant. 
 
(Sreelatha & Padma, 2009; 
Ndhlala et al., 2014) 
Aqueous leaf extracts 
anti-tumor  
 
(Dawood and Fathy, 2014) Aqueous leaf extracts 
Anti-ulcer. 
 
(Verma et al., 2012; 
Charoensin, 2014) 
Aqueous leaf extracts 
Anti-dyslipidemia. 
 
(Chumark et al., 2008; 
Dawood & Fathy, 2014) 
Aqueous leaf extracts 
hepatoprotective  
 
(Abou-Zeid et al., 2016; El-
bakry et al., 2016). 




1.3.2.5 Hepatoprotective activity of Moringa oleifera. 
MO has extensively been studied pharmacologically to justify its broad traditional medicinal use, 
from which it could have hepatoprotective properties. The study by El-bakry et al., (2016) showed 
that aqueous extracts have protected against CCl4-induced acute hepatotoxicity through the 
restoration of the anti-oxidative defense system and down-regulation of the pro-inflammatory 
pathway. 
A previous study showed that MO has hepatoprotective activity against the hepatotoxic effects of 
acetaminophen (Abou-zeid et al., 2016). In that study, the protective effects of MO alcoholic leaf 
extracts against the hepatotoxicity induced by acetaminophen were examined on isolated rat 
hepatocytes (Abou-zeid et al., 2016). The first set of hepatocytes was exposed to acetaminophen. 
Other sets of hepatocytes were preincubated with MO extract for 30 minutes before exposure to 
acetaminophen. Cell viability and enzyme (Lactate Dehydrogenase (LDH), ASAT & ALAT) 
leakage were assessed. As a result, acetaminophen reduced the hepatocyte viability and increased 
leakage of LDH, ASAT, and ALAT into incubation medium in a time-dependent manner. 
However, pretreatment of hepatocytes with MO extract showed increased cell viability, reduced 
ASAT and ALAT leakage and reduced lipid peroxide levels (Abou-zeid et al., 2016). 
MO has shown protection against cadmium-induced hepatotoxicity. Oral administration of 
cadmium chloride to Wistar albino rats for 28 days showed a significant increase in alkaline 
phosphatase (ALP), ALAT, ASAT, lipid peroxidation (LPO) and a decrease in superoxide 
dismutase (SOD), an increase in cadmium accumulation in the liver. Treatment with MO 500 
mg/kg significantly decreased the elevated ALAT, ASAT, ALP, LPO levels and an increase of 
SOD levels, as compared to cadmium chloride treated group (Toppo et al., 2015). 
In the study conducted by Saalu et al., (2012), alcohol was administered to induce hepatotoxicity 
in Wistar rats. Assessment of the liver histology, liver oxidative stress and the activities of liver 
biomarker enzymes was done in order to investigate the capabilities of polyphenolic antioxidant-
rich MO leaf extract to ameliorate liver derangement caused by alcohol. As outcomes, post-
treatment with MO leaf extract attenuated liver morphological, dysfunctional and oxidative status 
changes mediated by alcohol ingestion.  
These hepatoprotective properties have been shown to be due to the antioxidant activity of 
Moringa oleifera (phenolic compounds including flavonoids: kaempferol, rhamnetin, quercetin, 
chlorogenic acid, rutin, apigenin). 
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It has been reported that oxidative stress plays a main role in the initiation and progression of a 
variety of liver diseases, and many natural antioxidants have been tried to prevent oxidative stress-
mediated liver injury (Xie et al., 2012). 
In the absence of reliable therapeutic agents that can protect the liver from damage in modern 
medicine, remedies from medicinal plants are recommended to stimulate liver functions. Anti-
diabetic effects of MO have previously been demonstrated (Aja et al., 2015). Diabetes is associated 
with hepatotoxicity. This study aims to investigate whether Moringa oleifera could mitigate 
hepatotoxicity associated with diabetes mellitus. 
 
1.4 HYPOTHESIS, AIM AND OBJECTIVES. 
 
1.4.1 Hypothesis: 
Moringa oleifera leaf extracts have hepatoprotective effects in streptozotocin-induced diabetes. 
 
 1.4.2 Aim: 
To investigate the hepatoprotective effects of Moringa oleifera in streptozotocin-induced 
diabetes. 
1.4.3 Objectives: 
 To determine the effects of MO extracts on glucose intolerance in streptozotocin-induced 
diabetes. 











1.5 MATERIALS AND METHODS 
 
1.5.1 Drugs and chemicals. 
All chemicals and reagents were purchased from Sigma Aldrich Pty. Ltd., Johannesburg, South 
Africa.  Streptozotocin, citric acid, sodium phosphate, potassium chloride, methanol, phosphate 
buffer, sodium citrate, sodium chloride, ALAT activity assay kit, ASAT activity assay kit, GGT 
activity calorimetric assay, insulin ELISA kit, and BCP albumin assay kit were used in the study. 
Normal saline, insulin, glucometer, and glucometer test strips were purchased from a local 
pharmacy in Durban-South Africa. Two thousand grams of fresh leaves of fully grown Moringa 
oleifera were locally collected in Durban, South Africa. The harvested leaves and parts of the plant 
were identified and confirmed by Professor Himansu Baijnath of School of Life Sciences, 
University of KwaZulu-Natal, South Africa. 
1.5.2 Animals. 
Male Wistar rats (250-300 g) were procured from the Biomedical Resource Unit (BRU) of the 
University of KwaZulu-Natal, Durban, South Africa. They were kept in cages and housed in the 
animal holding facility; and exposed to a 12-hour light, 12-hour darkness cycle in a controlled 
room (temperature 24±1˚c, humidity 55%±5%). Animals had free access to standard commercial 
chow and drinking tap water. They were treated with humane care according to the guidelines of 
the Animal Research Ethics Committee of the University of KwaZulu- Natal; Ethical clearance 
number: AREC/038/017M. 
1.5.3 Preparation of the plant. 
The fresh plant samples (leaves) collected were washed under running tap water to remove soil 
particles and other dirt. The leaves of Moringa oleifera were air-dried at room temperature (23 ± 
2⁰C) for 12 days. The dried leaves were pulverized to fine granules using an electric grinder. 
Method of  Anwar et al., (2013) was adopted for the preparation of water and aqueous-methanol 
extracts. For the aqueous extract, 100 g of dry MO leaf powder was weighed and soaked into a 
500 ml of distilled water in volumetric flasks. Water was gradually added to this flask and the flask 
moderately shaken until of uniform consistency was formed. The constituents were then stirred by 
use of a magnetic stirrer for 48 h and thereafter centrifuged at 3000 revolutions per minute (RPM) 
for 10 min. The extract was then passed through a Whatman N⁰1 filter paper (24 cm). The residues 
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were extracted by the same procedure. A mixture of water and methanol (20:80 v/v) was gradually 
added to this flask and the flask was gently shaken until a slurry of uniform consistency was 
formed. Supernatant collected was poured into a round-bottomed flask. 
Due to the different boiling points of water and methanol, the round-bottomed flask was then 
attached to a rotary evaporator (EYELA, SB-651, Rik.kikai co.Ltd.Tokyo, Japan) at 40 °C. After 
running for 8h, methanol was removed. Finally, the extract was weighted and stored at -4˚C until 
use. 
1.5.4 Experimental design. 
After one week acclimatization period, the rats were randomly assigned into six 6 groups (n=7) as 
follows: Group A was orally treated daily with 3.0 ml/kg/body weight (BW) of distilled water; 
group C was similarly treated with MO (500 mg/kg/BW) daily. Groups B, D, E, and F were 
rendered diabetic by a single intraperitoneal injection of STZ (45 mg/kg/BW in 0.1M citrate buffer, 
pH4.5). Diabetes was confirmed 3 days later. Additionally, group D was treated with subcutaneous 
insulin (2 U/kg/BW, bid) while groups E and F were orally treated daily with MO 250 mg/kg/BW 
and 500 mg/kg/BW, respectively. Administration of STZ was done on day 1. Administration of 
MO/insulin started three days later when hyperglycemia was established. 
 
Table 6: Animal treatment protocol 
 
Treatment Distilled Water MO  MO STZ Insulin 
Groups ml/kg BW mg/kg BW mg/kg BW mg/kg BW IU/kg BW 
A 3.0 Nil Nil Nil Nil 
B Nil Nil Nil 45 Nil 
C Nil Nil 500 Nil Nil 
D Nil Nil Nil 45 2.0 
E Nil 250 Nil 45 Nil 





Only 500 mg/kg BW of MO was used to treat non-diabetic rats. This dose displayed the maximum of 
effects that could have been displayed when using 250 mg/kg BW. 
 
1.5.5 Induction of diabetes 
 
 Preparation of citrate buffer and STZ solutions. 
 
Citrate buffer (0.1 M, pH 4.4): To prepare 0.1 M citrate buffer (pH 4.4), 1.92 g of citric acid 
crystals (MW of 192.12, Sigma Aldrich, Johannesburg, South Africa) and 2.94 g of sodium citrate 
dihydrate (M.W. of 294.10, BDH Merck Ltd., Poole, England) were separately dissolved in 100 
ml of distilled water. Then, these two solutions were mixed together to adjust the pH 4.4 by using 
a pH meter (Lasec SA (Pty) Ltd). 
Normal saline (0.9% NaCl) solution: A 0.9 g of sodium chloride (M.W. of 58.44, Merck 
Chemicals (PTY) LTD) was dissolved in 100 ml of distilled water. 
 
Streptozotocin solution: 333 mg of STZ was dissolved in 26 ml of citrate buffer (12 mg/ml) and 
administered at 45 mg/kg BW to the rats. 
Diabetes was induced in animals of groups B, D, E and F by single intraperitoneal injection of 
STZ (45.0 mg/kg body weight) dissolved in 0.2 mL of 0.1 M citrate buffer, pH 4.5. Three days 
after STZ administration, development of hyperglycemia was confirmed by tail picking to analyze 
blood glucose levels using glucometer machine with trips. Rats with fasting blood glucose (FBG) 
more than 6.0 mmol/L were included in the study.   
Body weights were measured daily. Body weights were measured daily. Seven rats were housed 
per cage. Graduated bottles of water were placed on animal cages. Calculation of average 
consumption per cage was expressed by kilogram of body weight.  
 
1.5.6 Glucose Tolerance Tests (GTT). 
Glucose tolerance tests (GTT) were done on day 47 of the animal treatment. After an overnight 
fast for 8 hours, rats in all groups were intraperitoneally dosed with a D-glucose solution (3.0 g/kg 
BW) in 0.9% normal saline. This solution was prepared by dissolving 45 g of D-glucose anhydrous 
36 
 
in 60 ml distilled water (0.75 g/ml). Blood glucose concentrations were measured by tail pricking 
at 0, 30, 60, 90, and 120 minutes, using glucometer (OneTouch select®; Lifescan Inc., Milpitas, 
California, USA).  
The Area under the Curve (AUC) was calculated from blood glucose-time curves and presented 
as AUC units (mg/dl/min) (Scheff et al., 2012). On day 54 of treatment, animals were sacrificed 
by halothane overdose. Blood was collected by cardiac puncture in heparinized tubes then 
separated into plasma and stored at -80˚C for further biochemical analysis. Livers were excised, 
snap-frozen in liquid nitrogen and similarly stored for histological analysis. 
 
1.5.7 Plasma Insulin concentrations and calculation of HOMA-IR score. 
 
An ultrasensitive rat insulin ELISA kit was used to determine the concentration of insulin as per 
manufacturer’s instructions. Calibrators (25 µl), and the plasma samples in triplicate were pipetted 
into the 96 well microtiter-plate. One hundred (100) µl of the enzyme conjugate solution was then 
added into each well. This was then followed by incubation on a plate shaker at 700-900 rpm for 
2 hours at room temperature. The plate was then washed 6 times with 700 µl of washing buffer 
solution per well.  After the final wash, the plate was inverted and tapped on dry absorbent paper 
in order to remove excess washing buffer. Two hundred (200) µl of substrate IMP was then added 
into each well. The plate was then incubated at room temperature for 15 minutes. Fifty (50) µl of 
the stop solution was then added and then the microtiter plate was placed on the plate shaker for 5 
seconds in order to ensure a maximum reaction. The microtiter plate was then measured at 450 
nm.   
Insulin resistance was calculated by using the Homeostasis Model Assessment of Insulin 
resistance (HOMA-IR) equation (Gayoso-diz et al., 2013): 
Insulin Resistance = [Fasting Plasma Insulin (μU/ml) x Fasting plasma glucose (mmol/L)]/22.5].  
 








1.5.8 Liver function tests 
 
 Alanine amino transaminase (ALAT):  
 
Alanine aminotransaminase (ALAT) is an enzyme involved in the metabolism of the amino acid 
alanine. ALAT works in a number of tissues, but its highest concentrations are in the liver. An 
increase of serum ALAT levels in blood circulation has been used as an indicator for liver injury 
(Arun et al., 2012). ALAT catalyzes the transfer of amino groups from alanine to α- ketoglutarate 
which generates pyruvate and glutamate. Lactate dehydrogenase reduces lactate to pyruvate and 
oxidizes NADH to NAD. The rate of decrease in absorbance of the reaction mixture at 340 nm, 
due to the oxidation of NADH is directly proportional to the ALAT activity. 
 
L-Alamine + α- Ketoglutarate            Alamine  Transaminase                 Pyruvate + L-Glutamate. 
 
Pyruvate + NADH                  Hexokinase                  L-Lactate + NAD. 
 
 Aspartate amino transaminase (ASAT):  
Aspartate amino transaminase (ASAT) formerly called serum glutamate-oxaloacetate 
transaminase (SGOT), plays a role in catalyzing the transfer of amino groups from aspartic acid to 
α-ketoglutarate which generates oxaloacetate and glutamate. Malate dehydrogenase reduces 
oxaloacetate to malate and oxidizes NADH to NAD. The rate of decrease in absorbance of the 
reaction mixture at 340 nm, due to the oxidation of NADH is directly proportional to the ALAT 
activity. 
 
L-Aspartate + α-Ketoglutarate           Aspartate amino Transaminase           Oxaloacetate + L-Glutamate. 
 
 





 Gamma Glutamyl transferase (GGT). 
 
Gamma-Glutamyltransferase is membrane-bound protein that catalyze the transfer of Gamma-
glutamyl moiety from Gamma-glutamyl peptides to other peptides such as glutathione and to L-
amino acids. Serum GGT levels can be elevated in many pathophysiological conditions such as 
cardiovascular disease, metabolic syndrome, and chronic liver disease. Elevated serum levels of 
GGT can also be indicative of oxidative stress. GGT is the most specific marker for liver injury. 
 
Amino acid + Glutathione        Gamma-glutamyl transferase-              Glutamyl amino acid + Cysteinylglycine. 
 
 Albumin 
Albumin is produced in the liver and makes up 60% of plasma protein. Albumin plays an important 
physiological role in maintaining the osmotic pressure of plasma. Also, albumin binds and 
transports drugs, vitamins, and other molecules. Albumin is measured as an endpoint reaction with 
albumin binding to Bromocresol green (BCG), which is an anionic dye, in an acidic environment. 
The increase in absorbance at 620 nm of the green colored product is relative to the albumin 
concentrations in the sample (Moman and Bhimji, S., 2018 ). 
 
1.5.9 Histological analysis. 
A standard laboratory protocol for paraffin embedding was followed in processing the formalin-
preserved liver tissues. Liver specimens excised from experimental animals were washed and fixed 
in 10% buffered formalin. Tissues were processed by embedding in paraffin and sectioned (4 μm 
thickness). Thereafter, p-xylene was used to deparaffinize the slides which were then rehydrated 
in ethanol concentration gradient (100%, 80%, 70%, and 50%) and rinsed with tap water (Essawy 
et al., 2012). After, the hematoxylin and eosin were used to stain the slides for 5 minutes which 
were rinsed with water. As a final point, the slides were mounted in DPX, cover-slipped and 







1.5.10 Statistical analysis  
Data were expressed as mean ± standard deviation. One-way ANOVA or student t-tests were used 
to determine statistical significance for normal distribution data, while KRUSKAL-WALLIS H or 
Mann-WHITNEY U (Nonparametric tests) were used for non-normal distribution. GraphPad 
Prism Software Version 5.0. (GraphPad Prism® Software, Inc. San Diego, CA, USA) was used to 
compare the statistical difference between control means and treatment groups. Values of p < 0.05 
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After presenting the literature review, methods, aim and objectives of the study in 
chapter one, the general findings, discussion and results of the study were further 
reported in chapter two. A paper was presented in the form of a manuscript titled 
“Hepatoprotective effects of Moringa oleifera leaf extracts in streptozotocin-induced 
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Effects of methanolic leaf extracts of Moringa oleifera (MO) on hepatic injury in streptozotocin 
(STZ)-induced diabetes were investigated.  
Male Wistar rats were divided into 6 groups (n=7). Animals in group A were orally treated daily 
with 3.0 ml/kg/body weight (BW) of distilled water, while groups C, E and F were similarly treated 
with 500, 250 and 500 mg/kg/BW, respectively with MO. Groups B, D, E and F were rendered 
diabetic by single intraperitoneal injections of 45 mg/kg/BW of STZ. Additionally, group D was 
treated with subcutaneous insulin (2.0 U/kg/BW, bid).  
Diabetic animals exhibited significant weight loss, polydipsia, impaired glucose tolerance, fasting 
hypoinsulinemia and impaired liver function tests compared to controls. Treatment with MO 
methanolic leaf extracts significantly improved weight loss, polydipsia, glucose tolerance and also 
liver function tests in diabetic animals.   
MO has dose-dependent antidiabetic and hepatoprotective effects. 
Keywords 
Moringa oleifera, diabetes, streptozotocin, liver. 
Abbreviations 
ADA, American diabetes association; ANOVA, one way analysis of variance; ALAT, Alanine 
Aminotransaminase; ASAT, Aspartate Aminotransaminase; AUC, areas under the curve; BW, 
body weight; FBG, fasting blood glucose; FPI, fasting plasma insulin; GC-MS chromatography-
mass spectrometry; GGT, gamma-glutamyl aminotransaminase; MO, Moringa oleifera; OGGT, 






Diabetes mellitus is associated with increased morbidity and mortality globally and 425 million 
adults aged between 20 and 79 years were diagnosed with diabetes in 2017 (IDF, 2018; Ogurtsova 
et al., 2017).  Due to defects in insulin secretion, insulin action, or both persistent hyperglycemia 
affects carbohydrate, lipid and protein metabolism (ADA, 2017). Long term complications include 
hepatic injury characterized by cirrhosis, inflammation, apoptosis, and microvascular and 
macrovascular aberrations (ADA 2009 ). 
Liver function tests are commonly used in clinical practice to diagnose and monitor liver diseases. 
Liver enzymes such as Alanine Aminotransferase (ALAT; EC 2.6.1.2), Aspartate 
Aminotransferase (ASAT; EC 2.6.1.1), Gama-glutamylaminotransferase (GGT; EC 2.3.2.2) and 
albumin are routinely used as biomarkers for hepatocyte integrity (Harris, 2005). GGT is more 
specific to liver injury, is responsible for the catabolism of extracellular glutathione and is elevated 
in conditions of increased oxidative stress and inflammation such as diabetes (Wang et al, 2016). 
ALAT is specific for hepatocyte necrosis and although ASAT levels may be elevated in other 
conditions such as heart failure or myocardial infarction, increased levels are also indicative of 
liver disease. The liver synthesizes albumin, and hepatocellular inflammation and increased 
oxidative stress which are common conditions in persistent hyperglycemia is known to cause 
hypoalbuminemia (Levitt &Levitt, 2016). 
It has been reported that 80% of the world’s population use traditional medicines in primary 
healthcare due to their abundance, affordability, safety, and efficacy (WHO Traditional Medicine 
& Strategy, 2014). In South Africa for example, 80% of the population uses some sort of traditional 
medicines to meet their primary health care needs (van Wyk, 2008). One of such medicinal plants 
is MO which is commonly called “drumstick tree” in English, "Zogale" and "George," in Hausa 
and Igala languages of Nigeria, respectively (Atawodi et al., 2010). MO was first discovered in 
India, Asia and some parts of Western Africa in countries such as Ghana and Senegal (Booth, 
1988). In the Limpopo province of South Africa, MO is grown by small scale farmers and the 
leaves processed into a powder that is sold commercially in local markets (Mabapa et al, 2017). 
The leaves can be harvested as early as 3 months post-planting for domestic use as a food source 
or dried to concentrate nutrients and facilitate preservation, then ground by traditional methods 
into fine powder that acts as feed source for both humans and domestic animals (Mabapa et al, 
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2017; Moyo et al., 2011; Maroyi, 2006; Gadziray at al., 2013). MO has 13 drought resistant sub-
species that are fast growing (up to 6-7 m/year) in different parts of the world (Mabapa et al., 2017; 
Odee, 1998). In the province of KwaZulu-Natal, as in the rest of the country, traditional healers 
use different morphological parts of the plant to treat infectious, chronic and acute degenerative 
ailments.  
It has since emerged that MO has human and animal nutritive value owing to the high contents of 
proteins, flavonoids, vitamins and minerals such as calcium, iron, magnesium, and phosphorus 
(Gowrishankar et al., 2010; Chinedu et al., 2014; Mishra et al., 2011). Furthermore, MO extracts 
have been credited with pharmacological effects such as antioxidant (Charoensin, 2014; Ndhlala 
et al., 2014), antiatherosclerotic and hypolipidemic (Chumark et al., 2008; Yassa & Tohamy, 
2014), antineoplastic (Charoensin, 2014; Yassa & Tohamy, 2014; Vasanth et al, 2014 ), antipyretic 
(Aney et al., 2009), anti-inflammatory, antispasmodic and diuretic (Anwar et al., 2007), 
antibacterial (Ndhlala et al., 2014), antifungal (Kekuda et al., 2010), anti-hyperglycemic (Edoga 
et al., 2013) and hepatoprotective effects (Abou-Zeid et al., 2016; El-bakry et al., 2016). 
Glucotoxicity associated with diabetes is known to cause inflammation and oxidative stress which 
interfere with lipid and glucose metabolism (Mota et al, 2016). A Japanese Society of Diabetes 
study previously reported that the leading cause of death in patients with diabetes mellitus was a 
chronic liver disease (Shima et al, 2013). It is envisaged that with the high prevalence of type 2 
diabetes globally (Ogurtsova et al., 2017), a significant number of people could be afflicted with 
hepatic dysfunctions secondary to chronic hyperglycemia.   
To the best of our knowledge, the effects of MO leaf extracts on hyperglycemia-related 
hepatotoxicity have not previously been studied. It is envisaged in this study that besides its known 
antihyperglycemic effects, MO leaf extracts could mitigate the development of hyperglycemia-









2.0 Materials and Methods 
2.1 Reagents 
All chemicals and reagents unless otherwise stated were purchased from Sigma Aldrich Pty. Ltd., 
Johannesburg, South Africa. Diagnostic kits for insulin, ALAT, ASAT, GGT and albumin, 
streptozotocin, citric acid, sodium phosphate, potassium chloride, methanol, phosphate buffer, 
sodium citrate, sodium chloride were used in the study. Normal saline, insulin, glucometer, and 
glucometer test strips were purchased from a local pharmacy in Durban, South Africa. 
2.2 Plant material and preparation of methanol extracts. 
Two thousand grams fresh leaves of MO were collected in Durban, South Africa and identified by 
an expert Botanist at the herbarium in the School of Life Sciences, University of KwaZulu-Natal. 
The leaves were then washed with running tap water to remove soil particles and other dirt, and 
air-dried under room temperature (30 ± 2⁰ C) for 12 days. The dried leaves were pulverized to fine 
granules using an electric grinder. Water and aqueous-methanol extracts were prepared according 
to the modified methods of Makkar et al, (1996) and Sultana and Anwar, (2007). Briefly, 100 g of 
dry MO leaf powder was weighed and soaked in 500 ml of distilled water in a volumetric flask. 
Water was gradually added to the flask which was then shaken with a magnetic stirrer for 48 hours 
until a slurry of uniform consistency was formed and then centrifuged at 3000 rpm for 10 min. The 
extract was then filtered by Whatman filter paper (24 cm). The residue was re-extracted and a 
mixture of water and methanol (20:80 v/v) gradually added to this flask with gentle shaking until 
a slurry of uniform consistency was again formed. Supernatants collected were dispensed into 
round-bottomed flasks which were then rotary evaporated at 40 °C. Finally, the dried extract 
residues were weighed and stored at -4˚C until use. 
2.3 Gas Chromatography-Mass Spectrometry (GC-MS) analysis 
A PerkinEmler® Gas Chromatography (Clarus® 580) equipped with MSD mass spectrometer 
(Clarus® SQ8S) instrument with built-in autosampler was used carry out GC-MS analysis. 
Analytical parameters were set as Elite-5MS (30 m x 0.25 mm id x 0.25 μm) column; oven 
temperature 37 to 320°C at a rate of 18-25°C/min and held for 0.5 and 1.85 mins at 18 and 320 
°C, respectively; injector temperature was 250°C; MS Ion Source temperature was 280°C with full 
scan and solvent delay of 0–2.30 min; ms scan Range was m/z 35 – 500 in 0.10 sec ; carrier gas 
was Heat split flow of 20 ml/min; sample volume was 1.0 µl.  
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2.4 Animals treatment. 
Male Wistar rats (250-300 g) were procured from the Biomedical Resource Unit (BRU) of the 
University of KwaZulu-Natal. They were kept in cages and housed in the animal holding room 
facility and exposed to a 12-hour light/dark cycle in a controlled room (temperature 24±1ᴼC, 
humidity 55±5%). The animals had free access to standard commercial chow and tap drinking 
water. They were treated with humane care according to the guidelines of the Animal Research 
Ethics Committee of the University of KwaZulu-Natal; Ethical clearance number: 
AREC/038/017M. 
2.5 Experimental design and protocol 
After one week of acclimatization, the rats were randomly divided into 6 groups (n=7). Rats in 
group A served as normal control and were daily orally dosed with 3.0 ml/kg body weight (BW) 
of distilled water. Groups B, D, E, and F were rendered diabetic by a single intraperitoneal injection 
of 45 mg/kg BW of streptozotocin (STZ) in 0.2 ml of 0.1 M citrate buffer pH 4.5, after an overnight 
fast. Rats in groups C and F were orally treated daily with 500 mg/kg BW of MO. Group E was 
orally treated daily with 250 mg/kg BW of MO. Additionally, group D animals were treated with 
subcutaneous injections of insulin (2.0 IU bid), (Table 1). Administration of STZ was done on day 
1. Administration of MO/insulin started three days later when hyperglycemia was established. 
Table 1. Animal treatment protocol. The animals were orally treated daily with distilled water, 
MO methanolic leaf extracts, regular insulin and a single intraperitoneal injection of STZ in citrate 
buffer, respectively. (BW = Body Weight). 
Treatment Distilled Water MO  MO STZ Insulin 
Groups ml/kg BW mg/kg BW mg/kg BW mg/kg BW IU/kg BW 
A 3.0 Nil Nil Nil Nil 
B Nil Nil Nil 45 Nil 
C Nil Nil 500 Nil Nil 
D Nil Nil Nil 45 2.0 
E Nil 250 Nil 45 Nil 




Three days after STZ administration, development of diabetes was confirmed by tail pricking to 
analyze blood glucose levels using hand-held glucometer with trips. Rats with fasting blood 
glucose (FBG) more than 6.0 mmol/L were included in the study. Administration of MO/insulin 
starts immediately after confirmation of diabetes and ends 24 hours before the sacrifice of animals. 
Animals were treated consecutively for 53 days, they were sacrificed 24 hours after the last 
treatment or dose of MO/insulin. GTT was done by intraperitoneal injection of 3.0 g/kg BW of D-
glucose in 0.9% normal saline on day 47 after an overnight fast. Blood glucose concentrations 
were similarly measured at 0, 30, 60, 90, and 120 minutes. Areas under the Curve (AUC) were 
calculated from blood glucose-time plots and expressed as AUC units (millimoles /liter X 
minutes). The animals were then sacrificed by halothane overdose after 54 days and blood drawn 
by cardiac puncture in heparinized tubes and separated into plasma that was kept at -80ᴼC for 
further biochemical analysis. Livers were excised, divided into equal halves which were either 
snap-frozen in liquid nitrogen for further biochemical analysis or kept in phosphate buffered-
formalin for histological analysis. 
2.5.1 Liver function tests   
Liver function biomarkers ALAT, ASAT, GGT, and Albumin were measured by commercial kits 
as per the manufacturer’s instructions. 
 
2.5.2 Fasting plasma insulin 
Plasma insulin levels were analyzed by ultrasensitive rat insulin enzyme-linked immunoassay kit 
(DRG Instruments GmbH., Marburg, Germany) as per the manufacturer’s instructions. 
 
2.5.3 Histological analysis 
Standard laboratory protocol for paraffin embedding was followed in the processing of the 
formalin-preserved liver tissues. The livers were washed and fixed in 10% phosphate-buffered 
formalin. The tissues were then embedded in paraffin and sectioned into slices of 4 μm thickness. 
Thereafter, p-xylene was used to deparaffinize the slides which were then rehydrated in ethanol 
concentration gradient (100%, 80%, 70%, and 50%) and rinsed with tap water (Essawy et al, 
2012). Hematoxylin and eosin were used to stain the slides for 5 minutes then rinsed with water. 
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The slides were then mounted in Distyrene, Plasticizer and Xylene (DPX) resin, cover-slipped and 
viewed with Leica slide scanner (SCN 4000, Leicabiosystems Germany) (Yahya et al., 2013). 
2.6 Statistical analysis  
Data were expressed as mean ± standard deviation. One-way ANOVA or Student‘s t-tests were 
used to determine statistical significance for normal distribution data, while KRUSKAL-WALLIS 
H or Mann-WHITNEY U (Nonparametric tests) were used for non-normal distribution. GraphPad 
Prism Software Version 5.0. (GraphPad Prism® Software, Inc. San Diego, CA, USA) was used to 




3.1 GC-MS analysis 
Potentially bioactive constituents of the MO leaf extracts were separated and identified by GC-MS 
with an in-built automated mass spectral software that directly compared the peaks and retention 
times with those of standard compounds in the library following characteristic fragmentation 
patterns of mass spectra of the identified compounds. 
Identified compounds included hydrocarbons, acids, esters, alcohols, and aromatics. Most 
prominent peaks were identified as acetic acid, octyl ester, 2-pyrrolidinone, furan-2-carboxylic 
acid, malic acid, glycine, benzene acetic acid, 4-hydroxy-, ethyl ester,  D-galactopyranoside,  D-
glucopyranoside, 9H-pyrido[3,4-b]indole, cyclopentane, 1-isopropylidene-2-trimethylsilyl, cis-
7,10,13-Hexadecatrienal, benzyl-β-D-glucoside, octadecanoic acid, (2-phenyl-1,3-dioxolan-4-yl, 









Representative compounds identified by MS scans from integrated chromatogram peaks. The most 
prominent peaks are highlighted in bold. R.T (Retention Time), A/H (Area/Height ratio). 
 
Peak# R. Time Area Area% Height Height% A/H Name 
 3    3.028   231622    0.77   2639841    4.47   0.85   1-Propanamine, 2-methyl-N-(2-
methylpropylidene 
 6    3.661  746671   0.94   1952843   3.30   1.41   Butyrolactone  
 9    3.802   5289671   1.82   2484839   4.20   2.13    N-(2-Methylbutylidene)isobutylami  
10    3.877   1443668   0.50   740235   1.25   1.95    N-methylene-n-octylimine  
13    4.418   1961438   0.67   716172   1.21   2.74    Pyrazine, 2-ethyl-3-methyl-  
14    4.488   1035382   0.36   250872   0.42   4.13    2-Hexenoic acid  
15    4.606   2798953   0.96   593850   1.00   4.71    Acetic acid, octyl ester  
16    4.670   5652995   1.94   2934702   4.96   1.93   1-Butanamine, 2-methyl-N-(2-
methylbutylidene 
17    4.759   4000179   1.37   1448581   2.45   2.76    1-Butanamine, 3-methyl-N-(3-
methylbutylidene)-  
18   4.802   5501102   1.89   1410588   2.39   3.90    2-Propenoic acid, 2-methyl-, 1-
methylethyl ester 
20   5.095   5248693   1.80   1076697   1.82   4.87    2-Pyrrolidinone  
21   5.156   1785509   0.61   785709   1.33   2.27    [1,3]Diazepan-2,4-dione  
25   5.704   7071155   2.43   3259889   5.51   2.17    4H-Pyran-4-one, 2,3-dihydro-3,5-
dihydroxy-6 
26   5.834   2443005   0.84   849869   1.44   2.87    Ethyl hydrogen succinate  
28   6.005   1778374   0.61   422370   0.71   4.21    Furan-2-carboxylic acid [2,2,2-
trifluoro-1-(2-o 
30   6.274   3321809   1.14    944318   1.60   3.52    Benzofuran, 2,3-dihydro-  
32   6.502   1166600   0.40   338981   0.57   3.44    Benzeneacetic acid  
33   6.763   2078329   0.71   479400   0.81   4.34    Malic Acid  
35   7.034   1631466   0.56   565238   0.96   2.89    2-Methoxy-4-vinylphenol  
40   7.940   1095895   0.38   167187   0.28   6.55    Glycine, N-(trifluoroacetyl)-, 1-
methylbutyl ester  
42   8.282    2611355   0.90     874437   1.48    2.99     Benzeneacetonitrile, 4-hydroxy-  
63 
 
45   8.762   5525823   1.90   696614   1.18   7.93    Benzeneacetic acid, 4-hydroxy-, ethyl 
ester  
46    8.803   1382837   0.47    554126   0.94   2.50     1H-Pyrrole, 2-phenyl-  
48   9.003   1370724   
 
0.47   890099   1.51   1.54     1H-Pyrrole, 2-(2,4,6-cycloheptatrienyl)-  
51   9.325   1640494   0.56   617500   1.04   2.66    Megastigmatrienone  
52   9.388   1123407   0.39  410069   0.69   2.74   Ethyl 9-decenoate  
53    9.593   21509411   7.38   2913249   4.93   7.38   alpha.-D-Galactopyranoside, methyl  
54    9.720   47517811   16.31   3338788   5.65   14.23    Ethyl.alpha.-d-glucopyranoside  
55   9.943   15564596   5.34   1501540   2.54   10.37    Ethyl .alpha.-d-glucopyranoside  
60    10.982   18914584   6.49   1645304   2.78   11.50    Octyl-.beta.-D-glucopyranoside  
64   11.727   13643205   4.68   1876552   3.17   7.27    9H-Pyrido[3,4-b]indole  
65   11.807   28277500   9.70   2209710   3.74   12.80   Cyclopentane, 1-isopropylidene-2-
trimethylsilyl 
66   12.223   1560703   0.54   258284   0.44   6.04   cis,cis,cis-7,10,13-Hexadecatrienal  
68   12.985   3087096   1.06   490810   0.83   6.29    Benzyl .beta.-d-glucoside  
69   13.431   1589967   0.55   263882   0.45   6.03   Octadecanoic acid, (2-phenyl-1,3-
dioxolan-4-yl 
70   14.018   2609788   0.90   713437   1.21   3.66   2-Dimethyl(trimethylsilylmethyl)silyloxy 
methyltetrahydrofuran  
71   14.203   1251510   0.43   288339   0.49   4.34    3,5-O-Benzylidene-1-deoxy-d-gluco-d-
guloheptitol  
72   14.302   1402047    0.48   427768   0.72   3.28   beta.-l-Rhamnofuranoside, 5-O-acetyl-
thio-octy 










3.2.0 Evidence of diabetes 
3.2.1 Animal weights 
Diabetic rats exhibited significantly (p<0.05) reduced weight gain compared to controls. 
Treatment with either MO (500 mg/kg BW) or insulin significantly (p<0.05) reduced weight loss 
in diabetic rats compared to untreated diabetic group (Fig 1). There were no significant differences 
between MO treated non-diabetic and control rats or between MO-treated (250 mg/kg BW) and 
non-treated diabetic rats. There was a weight loss in the diabetic groups (Groups B, D, E, and F). 
 




















Fig. 1. Change in animal weights between day 0 and day 54 of treatment. A = controls; C= MO 
(500 mg/kg BW)-treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-
treated diabetic; E= MO (250 mg/kg BW)-treated, diabetic; F= MO (500 mg/kg BW)-treated, 








3.2.2 Water consumption 
Average water intake was significantly (p<0.05) higher in non-treated diabetic animals compared 
to controls. Treatment with either MO (500 mg/kg BW) or insulin (2.0 IU/kg BW, bid) 
significantly (p<0.05) reduced water intake in diabetic rats compared to non-treated diabetic rats 
(Fig. 2). There were no significant differences between MO treated non-diabetic and control rats 
or between MO-treated (250 mg/kg BW) and non-treated diabetic rats. 
 





























Fig. 2.  Average daily water consumption in treatment groups. A = controls; C= MO (500 mg/kg 
BW)-treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated, 
diabetic; E= MO (250 mg/kg BW)-treated, diabetic; F= MO (500 mg/kg BW)-treated, diabetic. 








3. 2.3 Fasting blood glucose 
FBG concentrations were significantly (p<0.05) elevated in non-treated diabetic animals compared 
to controls. Treatment with either MO (500 mg/kg BW) or insulin (2.0 IU/kg BW, bid) 
significantly (p<0.05) reduced FBG compared to non-treated diabetic animals (Fig. 3). There were 
no significant differences between MO treated non-diabetic and control rats or between MO-
treated (250 mg/kg BW) and non-treated diabetic rats. 
 
























Fig. 3. FBG concentrations measured after the animals were fasted overnight and blood drawn by 
tail pricking into a test strip and measured by a glucometer. A = controls; C= MO (500 mg/kg 
BW)-treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated 
diabetic; E= MO (250 mg/kg BW)-treated diabetic; F= MO (500 mg/kg BW)-treated, diabetic. (***, 








3.2.4 Fasting plasma insulin 
Fasting plasma insulin concentrations were significantly (p<0.05) reduced in non-treated diabetic 
rats compared to controls. Treatment with either MO or insulin (2.0 IU/kg BW, bid) significantly 
(p<0.05) improved fasting plasma insulin concentration in diabetic compared to non-treated 
diabetic rats. There were no significant differences between MO-treated non-diabetic and control 
rats (Fig. 4). 
 
 




























Fig. 4. Fasting plasma insulin measured in heparinized blood that was drawn by cardiac puncture 
after the animals were euthanized by halothane overdose. A = controls; C= MO (500 mg/kg BW)-
treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated diabetic; 
E= MO (250 mg/kg BW)-treated diabetic; F= MO (500 mg/kg BW)-treated, diabetic. (***, #, ^ 
p<0.05 compared to control (A), non-treated diabetic group (B) and MO (250 mg/kg BW)-treated 






3.2.5 Glucose tolerance 
Calculated AUC units from GTT suggested that untreated diabetic rats had significantly (p<0.05) 
increased glucose intolerance compared to controls. Treatment with MO or insulin (2.0 IU/kg BW) 
significantly reduced glucose intolerance in diabetic animals compared to the untreated diabetic 




























Fig. 5. Calculated AUCs from glucose tolerance curves in GTT. A = controls; C= MO (500 mg/kg 
BW)-treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated 
diabetic; E= MO (250 mg/kg BW)-treated diabetic; F= MO (500 mg/kg BW)-treated, diabetic. 








3.3.0 Liver function tests 
3.3.1 Liver enzymes 
Fasting plasma ALAT, ASAT and GGT concentrations were significantly (p<0.05) elevated in 
non-treated diabetic rats compared to controls (Fig 6A-C). Treatment with MO (either 500 or 250 
mg/kg BW) or insulin (2.0 IU/kg BW) significantly reduced plasma ALAT, ASAT and GGT levels 
in diabetic compared to non-treated diabetic rats. Treatment with MO (500 mg/kg BW) 
significantly (p<0.05) reduced plasma GGT concentrations in diabetic rats compared to MO (250 
mg/kg BW) (Fig 6C). There were no significant differences in liver enzymes between MO-treated 
non-diabetic and control rats. 
 
 
                                                                   A 
 
                                                                        B 


































                                                               C 
 
Fig 6. Fasting plasma A: ALAT; B: ASAT and C: GGT concentrations after the animals were 
euthanized by halothane overdose at the end of the treatment period and blood collected in 
heparinized tubes by cardiac puncture. A = controls; C= MO (500 mg/kg BW)-treated, non-
diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated diabetic; E= MO (250 
mg/kg BW)-treated diabetic; F= MO (500 mg/kg BW)-treated, diabetic. (***, #, $ p<0.05 
compared to control (A), non-treated diabetic group (B), and MO (250 mg/kg BW)-treated diabetic 
group (E), respectively.  



























































3.3.2 Plasma albumin 
Plasma albumin concentrations were significantly (p<0.05) reduced in non-treated diabetic rats 
compared to controls. Treatment with MO (either 500 or 250 mg/kg BW) or insulin (2.0 IU/kg 
BW) significantly (p<0.05) increased plasma albumin levels in diabetic compared to non-treated 
diabetic rats.  There were no significant differences in plasma albumin levels between MO-treated 
non-diabetic and control rats (Fig 7). 
 

















Fig. 7. Plasma albumin concentrations in blood that was collected by cardiac puncture in 
heparinized tubes at the end of the treatment period. A = controls; C= MO (500 mg/kg BW)-
treated, non-diabetic; B= Non-treated, diabetic; D= Insulin (2.0 IU/kg BW, bid)-treated diabetic; 
E= MO (250 mg/kg BW)-treated diabetic; F= MO (500 mg/kg BW)-treated, diabetic. (***, # 
p<0.05 compared to control (A) and non-treated diabetic group (B), respectively). 
3.4.0 Histological analysis 
The histopathological examination of liver sections from the control group (panel A) showed 
normal liver structure including central vein (CV) and hepatic cells (hp). However, non-treated 
diabetic rats (panel B) had livers with histopathological alterations such as degeneration of 
hepatocytes and inflammatory infiltrates with the fragmentation of the nucleus and cell lysis (F), 
necrotic hepatocytes (N), hepatic vein congestion (C), as well as vesicular cytoplasm (V). These 
pathological aberrations were absent in diabetic rats that were treated with either MO extracts or 
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insulin (panels E, F, D respectively) (Fig 8).  
 
      
      
      
Fig. 8. Hematoxylin and eosin stains of sections of liver tissues at the end of the treatment period. 
Panel A = controls showing normal liver structure including central vein (CV) and hepatic cells 
(hp);  Panel B= Non-treated, diabetic livers with degeneration of hepatocytes and inflammatory 
infiltrates with fragmentation of the nucleus and cell lysis (F), necrotic hepatocytes (N), hepatic 
vein congestion (C), as well as vesicular cytoplasm (V); Panel C= MO (500 mg/kg BW)-treated, 
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non-diabetic showing normal histopathology similar to controls; Pane D= Insulin (2.0 IU/kg BW, 
bid)-treated diabetic showing improved hepatocyte architecture; Panel E= MO (250 mg/kg BW)-
treated diabetic livers showing improved hepatocyte architecture similar to the insulin-treated 
diabetic group and Panel F= MO (500 mg/kg BW)-treated, diabetic livers with prominent central 
vein (CV), reduced hepatic vein congestion (C), necrotic hepatocytes (N), fragmentation of 
nucleus and cell lysis (F) and vesicular cytoplasm (V).  
 
4.0 Discussion  
This study was designed to investigate the hepatoprotective effects of MO methanolic leaf extracts 
in diabetic rats. Diabetes was induced by a single intraperitoneal injection of 45 mg/kg BW of STZ 
which partially destroyed pancreatic β-cells leading to hyperglycemia (El-mahmoudy et al, 2005; 
Szkudelski, 2001).  Our results here indicate that the animals were indeed diabetic with reduced 
weight gain (Fig. 1), polydipsia (Fig. 2), increased FBG (Fig. 3), reduced fasting plasma insulin 
(Fig. 4) and impaired glucose tolerance (Fig. 5). Treatment with MO methanolic leaf extracts (500 
mg/kg BW) significantly mitigated these symptoms of diabetes (Figs. 1-5). That treatment with 
250 mg/kg BW of MO methanolic leaf extracts only led to partial antidiabetic effects suggests that 
these pharmacological effects of MO are dose-dependent. Moringa oleifera contains alkaloids, 
flavonoids, glycoside, stilbenes and terpenoids as its bioactive compounds, which elicit their anti-
diabetic effect by causing an increase in insulin sensitivity or by inhibition of the intestinal 
absorption glucose or to the facilitation of metabolites in insulin-dependent processes (Gupta and 
Misra, 2006). 
This study found that insulin levels were increased in diabetic rats treated with MO extracts at 
different dosages (250 mg and 500 mg). This finding is in agreement with another study done by 
Anthanont et al., (2016). 
Hepatic injury associated with increased hyperglycemia has previously been documented (Mota 
et al., 2016; Sokolovska et al, 2015; Shima et al, 2013). In our study, degeneration of hepatocytes 
and inflammatory infiltrates with the fragmentation of the nucleus and cell lysis, necrotic 
hepatocytes, hepatic vein congestion, as well as vesicular cytoplasm were evident in non-treated 
diabetic rats (Fig. 8) similarly to previous reports (Kamalakkannan and Prince, 2006; Omodanisi 
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et al, 2017). However, treatment with MO just like insulin, restored some of these 
histopathological aberrations, suggesting a protective role of MO in hyperglycemia-associated 
hepatic injury. We have presented evidence of hepatocellular injury by measuring plasma levels 
of key enzymes that are used clinically in liver function tests. ALAT, ASAT, and GGT were all 
elevated in untreated diabetic rats but treatment with either MO methanolic leaf extracts or insulin 
significantly reduced plasma levels of these enzymes in diabetic animals (Fig. 6) yet there were no 
significant differences in these enzymes’ concentrations between MO-treated non-diabetic and 
control rats. That response in GGT levels was significantly lower with 500 than with 250 mg/kg 
BW of MO in diabetic animals suggests yet again that hepatoprotective effects of MO could be 
dose-dependent considering that, clinically GGT is a more reliable marker of hepatic injury than 
the other enzymes (Fig. 6C), (Wang et al, 2016). ). The reduction of ALAT, ASAT, and GGT 
concentration after MO treatment observed in this study is in agreement with another study by 
Gupta et al., (2014). 
The increased activities of these enzymes in diabetic rats in this study may be a result of 
hepatocellular damage caused by oxidative stress that results in the leakage of ALAT, ASAT, and 
GGT from liver cells. MO may contain many bioactive chemical constituents like carotenoids, 
coumarins, essential oil, flavonoids, glycosides, lignans, monoterpenes, reducing sugars, resins, 
stibeans, and saponins which could be responsible for the decrease of these enzymes (Aja et al., 
2014). Potentially, extract of MO could be increasing regenerative capacity of the β-cells to restore 
some of them to recover from damage caused by STZ. 
Our results further show that untreated diabetic animals had significant hypoalbuminemia 
compared to controls suggesting hyperglycemia-associated hepatocellular injury. Treatment with 
either MO methanolic leaf extracts or insulin significantly restored plasma albumin levels 
compared to untreated diabetic animals yet there were no significant differences between MO-
treated non-diabetic animals and controls (Fig. 7). Hypoalbuminemia is a strong clinical biomarker 
for hepatic inflammation and injury (Levitt and Levitt, 2016). 
Although our study has not clearly shown the mechanisms by which MO methanolic leaf extracts 
could be exerting hepatoprotective effects, it has previously been suggested that phenolic 
compounds (apigenin, kaempferol, quercitrin, chlorogenic acid, rutin, and rhamnetin) and 
flavonoids abundantly present in MO extracts could exert free radical-scavenging effects that 
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reduce inflammation and oxidative stress (Sreelatha and Padma 2009; Ndhlala et al., 2014; Ahmed 
and Urooj, 2009; Ramadan and Khalil, 2013). We have identified similar compounds to be present 
in our extracts, (Table 2) and therefore posit that MO ethanolic leaf extracts that we used in this 
study reduced inflammation and oxidative stress hence mitigated hyperglycemia-associated 
hepatic injury. Representative compounds identified by MS scans from integrated chromatogram 
peaks are presented in table 2. Prominent peaks are highlighted in bold. These compounds could 
have hepatoprotective activity. In this particular study, it is not clear if the activity resulted from a 
mixture of or individual compounds. Their significance as the bioactive chemical compound has 
not been previously determined. Hence future studies need to isolate them individually and test in 
vitro if they will have hepatoprotective activity.  
 
5.0 Conclusions 
Our study reported herein has shown that methanolic leaf extracts of MO have dose-dependent 
antidiabetic and hepatoprotective effects which could be attributed to its phenolic bioactive 
compounds. These findings, therefore, lend credence to the folkloric medicinal claims of 
hepatoprotective effects of MO leaf extracts by African traditional healers. Even though MO was 
originally from Asia, this plant has been grown in South Africa and also used in traditional 
medicine for the management of certain diseases, including diabetes. Further studies are needed 
to investigate phytochemical compounds responsible for the effects and the molecular 
mechanisms involved in hepatoprotective properties of MO. 
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CHAPTER 3: GENERAL DISCUSSION, CONCLUSION AND RECOMMANDATION. 
3.1 GENERAL DISCUSSION AND CONCLUSION  
 
This study was carried out to investigate whether Moringa oleifera could mitigate hepatotoxicity 
in diabetes mellitus. 
Because of its functional roles in the regulation of physiological processes in the body, the liver is 
prone to toxicity. Injury to the liver may affect the integrity of hepatocytes leading to the release 
of liver enzymes such as ALAT, ASAT, and GGT since these enzymes are commonly used as 
markers of liver injuries (Harris, 2005).  
In the present study, damage to the liver caused by diabetes was evident in plasma levels of ALAT, 
ASAT, GGT and albumin concentrations. Induction of diabetes significantly increased the plasma 
levels of liver enzymes (ALAT, ASAT, and GGT) and significantly decreased the plasma levels 
of albumin. This result indicates that acute hepatotoxicity and liver dysfunction may arise due to 
diabetes. After that, increase in the enzyme activities may mostly be due to leakage of these 
enzymes from the liver cells into the bloodstream which screen for the hepatotoxic effect of 
diabetes-mediated toxicity (Paremes et al., 2015). 
In conclusion, fasting plasma ALAT, ASAT and GGT concentrations were significantly (p<0.05) 
increased in non-treated diabetic rats compared to controls. Treatment with MO significantly 
decreased plasma ALAT, ASAT and GGT levels in diabetic compared to non-treated diabetic rats. 
Plasma albumin concentrations were significantly (p<0.05) decreased in non-treated diabetic rats 
compared to controls. Treatment with MO significantly (p<0.05) increased plasma albumin levels 
in diabetic compared to non-treated diabetic rats. 
Therefore, this result as shown by biochemical and histological analysis, support the hypothesis of 
this study and shows that the extract of Moringa oleifera grown in South Africa could mitigate 
hepatotoxicity associated with diabetes mellitus. This effect could be attributed to the presence of 
flavonoids and phenolic compounds (apigenin, kaempferol, quercitrin, chlorogenic acid, rutin, 





3.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
Further studies are needed to investigate phytochemical compounds responsible for the effects 
and the molecular mechanisms involved in hepatoprotective properties of MO.  
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Background: One of the most challenging health problems is liver disease, which can be caused 
by medications, toxic substances, and excessive consumption of alcohol. Liver problems can be 
also caused by infections, autoimmune disorders, and food. This study aims to establish evidence 
of the use of Moringa oleifera sub-Saharan African countries to manage liver damage, conditions 
in animals. 
Methods: In vivo studies will include those in which the activity of the serum levels of hepatic 
enzymes Alanine Transaminase (ALT) or serum glutamate-pyruvate transaminase (SGPT), 
Aspartate Transaminase (AST) or Serum Glutamic oxaloacetic transaminase (SGOT), Gama-
Glutamyltransferase (GGT) and/or Alkaline phosphatase (ALP) were measured after 
administering substances that induced liver injury as a primary outcome. 
The secondary outcome will include studies that measure the serum levels of hepatic enzymes 
(ALT, AST, GGT, and ALP) after administering the sub-Saharan Moringa oleifera, decreases in 
their levels indicating the improvement of their activity. 
Articles written in languages other than English and French will be excluded. Search engines will 
include MEDLINE, CINAHL, PubMed and Google Scholar. The screened results will be grouped 
according to any noteworthy grouping variable, such as study characteristics. 
 
Discussion: The results will give scientists new insight into the possible use of this plant to develop 
effective hepatoprotective drugs treat liver damage, and indicate areas of research for 
consideration. 
Systematic review registration: CRD42018084698. 
 
Keywords: Moringa oleifera, alanine aminotransferase, aspartate aminotransferase, Gamma-
glutamyltransferase, alkaline phosphatase, sub-Saharan Africa countries.  
 
 Background 
The liver plays a major role in regulating many of the body’s physiological processes such as its 
metabolic, vascular, immunological, storing, secretory and excretory functions. Furthermore, it is 
involved in detoxifying a variety of drugs and xenobiotics; and plays a key role in metabolizing 
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carbohydrate, protein, and fat in the human body [1]. However, the ability of the liver to achieve 
these functions is often inhibited by many substances which may cause liver diseases. Liver diseases 
are some of the most challenging health problems, which can be caused by the undesirable effects 
of some medications, toxic substances, excessive consumption of alcohol, infections and 
autoimmune disorders [2]. Liver diseases, which can cause death include cirrhosis, liver cancer, 
viral hepatitis (B, C, and D), non-alcoholic fatty liver diseases (NALD), alcoholic liver disease, 
autoimmune and drug-induced liver diseases [3]. The prevalence of non-alcoholic fatty liver 
disease was estimated to 20% worldwide in the general population in the year 2012 [4]. Two billion 
people were infected by hepatitis B worldwide in 2015, and 520,000 deaths were reported, with 
170 million being affected by hepatitis C [5]. In India, almost 20,000 deaths are reportedly due to 
liver diseases every year [6]. Europe reported 63,500 cases of liver cancer in the year 2012, with 
29 million people suffering from liver diseases in 2013. In the United States of America, 30 million 
people suffered from liver diseases versus 2013, with 170,000 deaths being reported due to liver 
cirrhosis [5].  
Alanine Transaminase (ALT), Aspartate Transaminase (AST) and Gama-Glutamyltransferase 
(GGT) are serum of hepatocellular enzymes that are normally found in the liver. ALT is the 
specific marker for liver injury, AST can provide information about other tissues including the 
heart and skeletal, while GGT is found in the kidney and pancreas [7]. The elevated levels of these 
enzymes in the serum is a sign of their increased entrance in serum from damaged liver cells 6, 
with injury being identified using enzymes as hepatic markers [8]. Studies have shown that the 
chances of the damaged liver being able to heal are reduced in the acute phase which often leads 
to chronic diseases with complications [9]. In spite of considerable progress in modern medicine, 
there are very few therapeutic agents that can protect the liver from damage and stimulate liver 
functions [10]. Patients with chronic liver disease are liable to have liver transplantation, which is 
not only costly but has long-term consequences of immunosuppressive agents, especially 
hyperlipidemia, hypertension and renal disease [11]. For these reasons, many patients with liver 
disease use herbal remedies to solve their health problems [12]. 
Moringa oleifera is cultivated worldwide, but native of India, Bangladesh, and Pakistan [13], being 
a wild and domestic tree in many sub-Sahara African countries. Phytochemical analyses have 
shown that its leaves contain various minerals, such as calcium, iron, phosphorous, potassium and 
vitamins (A, C and D) [14]. Its bark, flowers, fruits, leaves, pods, and roots possess many 
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biological and pharmacological properties, such as antibacterial, antidiabetic, anti-inflammatory, 
antifungal, antihypertensive, antioxidant, antipyretic, antispasmodic, antitumor, antiulcer, 
cholesterol lowering, diuretic and hepatoprotective activities [9]. The leaf extracts reportedly 
reduce serum intracellular enzymes levels by stabilizing the cell membrane, which prevents 
enzymes leakages [15]. While the agro-climatic conditions of vegetable materials may vary from 
one place to another; little is known about the different species of Moringa in sub-Saharan 
countries. This study, therefore, aims to establish the evidence of Moringa oleifera from sub-
Saharan Africa being used to manage liver damage, specifically in animals. The results will give 
scientists new insights into the possible use of this plant to develop effective hepatoprotective 
drugs against liver damage. 
Research questions 
For the purpose of this study, the general research question is as follows: Does Moringa oleifera 
from sub-Saharan African manage liver damage? To answer this general question, specific 
research questions have been developed: 
1. Does the administration of substances inducing liver damage increase the levels of hepatic 
enzyme activities (ALT, AST, GGT and/or ALP); 
2 Does Moringa oleifera from sub-Saharan African decrease the activity of hepatic 
enzymatic markers? 
The study objectives are: 
1 To establish whether substances inducing liver damage increase the levels of hepatic 
enzyme activities (ALT, AST, GGT and/or ALP). 
2 To determine whether Moringa oleifera decrease the activity of the hepatic enzymatic 
markers. 
Methods/ design 
This systematic review is reported following the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses Protocols (PRISMA-P) 2015 checklist (Additional File 1) [16]. This 
review protocol having been registered in the international prospective register of the systematic 






Studies using rats and mice will be selected. Also, studies using Moringa oleifera growing in sub-
Sahara African countries will be selected. 
Intervention 
The intervention will include studies in which administration of substance was done to induce liver 
damage in rats and mice. The intervention group will include also studies in which Moringa 
oleifera from sub-Saharan African was administered to treat the induced liver damage. 
Comparison 
The comparison will include studies in which groups of animals that have and have not been treated 
with Moringa oleifera from within African were compared. This comparison will be evaluated 
according to the level of liver markers such as ALT, AST, GGT and/or ALP. 
Types of outcomes 
Primary outcome 
The primary outcome will consist of studies in which the levels of hepatic enzymes activities of 
ALT, AST, GGT and ALP in the serum after administration of substances that induced liver 
damage were measured. Increase in the levels of those hepatic enzymes in serum would indicate 
damaged liver possibly caused by these substances. 
Secondary outcome 
The secondary outcome will consist of studies in which the levels of hepatic enzymes activities of 
ALT, AST, GGT and/or ALP in serum after administration of sub-Saharan African Moringa 
oleifera were measured. This can have positive, negative, or no effects when compared to standard 
treatment before and after the intervention. Decreases in the levels of those hepatic enzymes in the 
serum would indicate an improvement of their activity after the administration of Moringa oleifera 
(positive effect). Increases in the levels of those hepatic enzymes in the serum would indicate no 
improvement in their activity after the administration of Moringa oleifera (negative effect). Lastly, 
when there is no change of hepatic enzymes levels when compared to standard treatment before, 





Study eligibility criteria 
Inclusion Criteria 
Studies will be included in the systematic review if they satisfied all of the following: 
• English and French research published before December 31, 2018. 
• In vivo research on rats and mice treated with sub-Saharan African Moringa oleifera to 
manage the liver damage. 
• Where AST, ALT, GGT, and ALP are measured in the animals’ serum. 
• Case-control groups of treatment with and without Moringa oleifera. 
Exclusion criteria 
• Articles on human or animal study other than rats and mice. 
• Letters, reviews, case report and comments. 
• All articles without available full text. 
• Articles not addressing the hepatoprotective activity of Moringa oleifera. 
• Articles using co-administration with another plant. 
• Articles using Moringa oleifera not harvested in sub-Saharan Africa. 
• Case-control group of treatment with another plant than Moringa oleifera. 
 
Information sources and search strategy for identifying relevant studies 
A comprehensive and exhaustive search of CINAHL, Google Scholar, Medline, and PubMed 
Database will be performed to identify all relevant articles published on hepatoprotective 
properties of Moringa oleifera from sub-Saharan African countries before December 31, 2017, 
regardless of the language of publication. A search strategy based on the combination of relevant 
terms will be conceived and applied. The following terms and their variants will be used for 
Moringa oleifera:  “Moringa oleifera”, “Morungue”, “Drumstick tree”, “Horseradish tree”, “Ben 
tree”, “Moringueiro” and “Rawag”. For hepatoprotective, we will use the terms “Alanine 
Transaminase”, “Alamine Amino Transferase”, “serum glutamate-pyruvate transaminase”, 
“Aspartate Transaminase”, “Aspartate Amino Transferase”, “Serum Glutamic oxaloacetic 
transaminase”, “Gama-Glutamyltransferase” and “Alkaline phosphatase”. Individual country 
names for the 54 sub-Saharan African countries will also be used as additional key search terms 
for more abstracts on the subject. African country names will be introduced both in English and 
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languages relevant to each country for example, “Ivory Coast” and “Côte d’Ivoire”. Where country 
names have changed over time, old and new names will be included, such as “Zaire” and 
“Democratic Republic of Congo”. Abstracts of all eligible papers will be reviewed and full texts 
of articles will be accessed through CINAHL, Google Scholar, MEDLINE and PubMed. The main 
search strategy conducted in PubMed is shown in Table 1. This search strategy will be adapted for 
searching other databases. 
A manual search which consists of scanning the reference lists of eligible papers and other relevant 



























Table 1: Search strategy in PubMed 
Search Area Search terms 
#1 Moringa Moringa oleifera OR Morungue OR Drumstick tree OR 
Horseradish tree OR Ben tree OR Moringueiro OR Rawag 
#2 Hepatoprotective Alanine Transaminase OR Alamine Amino Transferase OR serum 
glutamate-pyruvate transaminase OR Aspartate Transaminase OR 
Aspartate Amino Transferase OR Serum Glutamic oxaloacetic 






(Algeria OR Angola OR Benin OR Botswana OR Burkina Faso 
OR Burundi OR Cameroon OR Canary Islands OR Cape Verde 
OR Central African Republic OR Chad OR Comoros OR Congo 
OR Democratic Republic of Congo OR Djibouti OR Egypt OR 
Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR 
Gambia OR Ghana OR Guinea OR Guinea Bissau OR Ivory 
Coast OR Cote d'Ivoire OR Jamahiriya OR Kenya OR Lesotho 
OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR Mayotte OR Morocco OR 
Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda 
OR Sao Tome OR Senegal OR Seychelles OR Sierra Leone OR 
Somalia OR South Africa OR St Helena OR Sudan OR 
Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR 
Western Sahara OR Zaire OR Zambia OR Zimbabwe OR sub 
Saharan Africa). 
 








Selection of studies 
All studies identified using selected keywords will be screened after removing duplicated articles. 
The first choice of inclusion criteria for this study will be based on titles and thereafter on abstracts 
if the title does not clearly give the information related to our study. Full articles will be found for 
detailed appreciation against the inclusion criteria before screened of articles. Finally, included 
articles for the study will be selected in using the above eligibility criteria. Assessment of studies 
for possible inclusion will be done by two reviewers, and any changes of views will be fixed 
through discussion until a compromise is reached. Any papers that are not unanimously excluded 
or included by both reviewers will be examined by both reviewers until an outcome is agreed. If 
necessary, a third person may be consulted. This will reduce the risk of bias. The review study 
selection process will be followed by a flow diagram showing the number of all excluded studies 
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Data extraction and management. 
A data extraction form will be created by the principal author (WTM) in Microsoft Excel and 
modified by feedback from three independent reviewers (MGK, MN, and PMOO) to ensure that 
complete data is obtained. Two review authors (WTM and MGK) will independently extract data. 
Data will be collected on the first author name; animal species (rats, mice), gender (male and/or 
female), age (mature adult, middle-aged, old adult), weight; nature of acute liver damage (drug, 
toxic chemical, alcohol, food, and infection or autoimmune induced damage); part of Moringa 
used (bark, flour, leaves, seed), African country of harvest, dose of Moringa administrated, 
duration of treatment; and primary and secondary outcome measurements. 
Disagreements between authors will be resolved through discussion and consensus, or arbitration 
by a third author whenever necessary. For managing missing data, we will contact the 
corresponding author of the respective studies in order to obtain the required details. If no 
correspondence is received, the study will be included in the systematic review and discussed in 
the narrative summary. 
Data analysis including an assessment of heterogeneity 
Data will be analyzed using Stata statistical software (Stata Corp V.14, Texas, USA).   
Study data will be quantitatively synthesized by first assessing heterogeneity to examine whether 
the estimates from included studies could be pooled. Heterogeneity will be assessed by the Chi-
squared test on Cochrane’s Q statistic, which will be quantified by I-squared values. Values of 25, 
50, and 75% for I-squared will be represented low, medium, and high heterogeneity, respectively 
[18]. When substantial heterogeneity will be detected, we will perform meta-regression and 
subgroup analyses to investigate the possible sources of heterogeneity using the following 
grouping variables: animal species (rat , mice), age (mature adult, middle-aged, old adult), gender 
(male, female, combination of genders used), weight; nature of acute liver damage (drug, toxic 
chemical, alcohol, food, and infection or autoimmune induced damage); part of Moringa used 
(Bark, flour, leaves, seed), African country of harvested, dose of Moringa administrated, duration 
of treatment; and outcome measurement results. The heterogeneity between subgroups will be 
detected by using the X2 test on Cochrane’s Q statistic. In cases where quantitative synthesis is not 
appropriate because it is not possible to conduct meta-analysis due to the heterogeneity of 
estimates reported by studies, a qualitative narrative synthesis of the evidence will be performed. 
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This will summarize the studies characteristics, animal’s features, nature of liver damage, Moringa 
features an outcome result. 
 
Assessment of risk of bias 
The study quality and the presence of potential bias within individual studies will be done at both 
the outcome level and the study level. Two reviewers (WTM and MGK) will complete the 
assessment independently. The Cochrane risk of bias tool will be used to assess publication bias, 
addressing assessments for random sequence generation, concealment of allocation, blinding and 
the outcome measurements, and completeness of outcome reporting [19]. Each bias criterion will 
be assigned a value of low, high, or unclear risk of bias for each included study. 
Visual assessment of the funnel plot and the Egger’s statistic will be used to assess for both the 
presence and statistical significance of publication bias across studies [20]. 
Assessment of methodological and evidence qualities. 
We will use the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) methodology to assess the quality of evidence for each outcome as recommended in 
the Cochrane Handbook for Systematic Reviews of Interventions [21]. Quality rating of overall 
evidence will be downgraded according to the following factors: Risk of bias, the inconsistency 
of result, indirectness, imprecision, and publication bias. In addition and where appropriate, the 
reasons to upgrade the evidence quality will include a large magnitude of effects, a dose-
response gradient, and plausible residual confounding that would reduce a demonstrated effect or 
suggest a spurious effect when results show no effect. We will integrate downgrading and 
upgrading factors to obtain an overall quality of evidence for each outcome of interest. Overall 
quality of evidence will be then ranked as high, moderate, low, or very low as specified by the 
GRADE approach [21; 22]. 
 
Discussion  
Moringa oleifera (MO) is a plant traditionally used for its medicinal and nutritional properties in 
Africa. Many studies have been done on MO, and some of them showed that MO possesses 
hepatoprotective activity [1]. But then, not many studies have focused on MO from sub-Saharan 
countries in managing acute liver damage induced. This protocol states the plan for a systematic 
review and meta-synthesis of the effectiveness of Moringa oleifera from sub-Saharan African 
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countries to manage liver damage. Therefore, this review will fill this gap by revealing evidence 
that Moringa oleifera from different countries of sub-Saharan Africa have the same effects on 
induced acute liver damage, so agro-climatic conditions of vegetable materials may vary from one 
place to another [23]. Results will be shared with the scientific community through publishing in 
a peer-reviewed journal. The findings could give scientists new insight into the possible use of this 
plant to develop effective hepatoprotective drugs that treat liver damage and can serve as valuable 
inputs for future research in this area. 
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